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SUMMARY 
 
Human Papillomavirus (HPV) are considered as the major etiologic cause for a 
variety of benign and malignant epithelial lesions.  The so-called high risk-HPV types 
are related to cervical cancer, while low-risk types are associated with benign mucosal 
lesions only. HPV types 16 and 18 are the most frequently found types in cervical 
cancers. Antibodies to HPV major capsid protein, L1, can develop in response to 
natural HPV infection as well as after vaccination. In contrast, antibodies to early, 
non-structural proteins, mainly E6 and E7 which are consistently expressed in HPV-
transformed cells, have been found to be strongly associated with invasive carcinoma. 
Virus-like particles (VLP) which mimic morphologically and immunologically the 
native virions have been used so far as standard serological antigens.  
This PhD thesis had two main objectives, first to characterize the bacterially 
expressed, affinity-purified glutathione S-transferase fusion proteins (GST) as 
alternative antigens for serology in terms of displayed epitope repertoire, using a 
panel of 92 VLP-specific monoclonal antibodies (mAb) generated against 9 mucosal 
alpha papillomavirus types. The second objective was to analyze in details the natural 
as well as HPV vaccine-induced immune response in patients with cervical 
intraepithelial neoplasias (CIN II/III). Additionally, an antibody blocking assay based 
on Maltose binding protein (MBP)-fusions was established to analyze the type-
specificity of HPV antibodies.     
It is shown here that GST-L1 fusion proteins display a broad variety of epitopes and 
thus are well suited for detection of human HPV antibodies. Cross-reactivity is 
associated with linear as well as conformational epitopes and can be intra- and/or 
interspecies specific and follows the phylogenetic relationships only loosely. 
Neutralizing epitopes are always conformational and mostly, but not always type-
specific. The established MBP-16L1 allowed blocking the binding of mono-specific 
as well as cross-reactive antibodies to GST-16L1 but not that of specific antibodies to 
other HPV types. 
Vaccination of patients with cervical intraepithelial neoplasias with HPV16L1/E7 
chimeric VLP induced strong 16L1 specific and weaker 16E7 specific responses as 
well as L1 neutralizing antibodies. The response was positively correlated with 
vaccine dose the immune status before vaccination. Vaccination-induced cross-
reactivity to both L1 and E7 was across species and the cross-reactive sera were non 
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cross-neutralizing for distantly related HPV. Chimeric VLP vaccination also induced 
antibody responses to other HPV16 early proteins suggesting that these proteins were 
released from the lesions in response to vaccination. 
In conclusion, bacterially expressed GST fusion proteins are good candidates to be 
used as antigens in HPV serology and are also useful tools to define and characterize 
the complex patterns of conformational and linear cross-reactive epitopes. 
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ZUSAMMENFASSUNG 
 
Humane Papillomviren (HPV) sind der wesentliche äthiologische Faktor für eine 
Reihe gutartiger und bösartiger epithelialer Läsionen. Die sogenannten Hoch-Risiko 
HPV Typen sind mit Gebärmutterhalskrebs assoziiert, Niedrig(Low)-Risiko Typen 
dagenegen nur mit gutartigen Schleimhautläsionen. Die HPV Typen 16 und 18 sind 
die häufigsten Typen in Gebärmutterhalskrebs. Antikörper gegen das 
Hauptkapsidprotein L1 können sich nach natürlicher Infektion aber auch nach 
Impfung entwickeln. Dagegen sind Antikörper gegen die frühen, 
Nichtstrukturproteine  E6 und E7, die konsistent in HPV-transformierten Zellen 
exprimiert werden, stark assoziiert mit invasivem Krebs. Virus-ähnliche Partikel 
(VLP) ahmen morhologisch und immunologisch native Virionen nach und sind bisher 
als Standardantigen für HPV Serologie verwendet worden. 
Die beiden wesentlichen Ziele dieser Dissertation sind: (i) Bakteriell exprimierte, 
affinitätsgereinigte Glutathion-S-Transferase (GST) Fusionsproteine sollten bezüglich 
des Epitoperepertoires als alternative Serologieantigene charakterisiert werden unter 
Verwendung von 92 VLP-spezifischen monoklonalen Antikörpern, die gegen 9 
mukosale Alpha-Papillomavirus Typen entwickelt worden sind. (ii) Die natürliche 
wie die durch HPV-Impfung induzierte humorale Immunantwort sollte in 
Patientinnen mit Gebärmutterhalskrebs-Vorstufen (CIN II/III) detailliert beschrieben 
werden. Weiterhin wurde ein Antikörper-Blockierungstest basierend auf 
Fusionsproteinen mit Maltose-Bindungsprotein (MBP) entwickelt für die Analyse von 
typspezifischen HPV-Antikörpern.  
Hier wird gezeigt, dass GST-L1 Fusionsproteine eine breite Epitope-Palette 
präsentieren und so gut geignet sind humane HPV-Antikörper zu bestimmen. 
Kreuzreaktivität ist assoziiert mit linearen und konformationellen Epitopen, sie kann 
intra-- und/oder interspezies spezifisch sein und folgt nur wenig den phylogenetischen 
Verwandtschaften. Neutralisierende Epitopes sind immer konformationell und 
meistens, aber nicht immer typspezifisch. Mit dem Fusionsprotein MBP-16L1 konnte 
sowohl die Bindung von mono-spezifischen als auch kreuzreaktiven Antikörpern an 
GST-16L1 gehemmt werden aber nicht die von  für andere HPV-Typen spefisiche 
Antikörpern an die entsprechenden Typen. 
In Seren von CIN II/III Patientinnen, die im Rahmen einer klinischen Studie mit 
HPV16L1/E7 chimären VLP geimpft worden waren, konnte die Induktion einer 
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starken Antikörperantwort gegen 16L1 und schwächer gegen 16E7 und von 
neutralisierenden Antikörpern nachgewiesen werden. Die Immunantwort war positiv 
korreliert mit der Vakzinedosis und mit dem Immunstatus vor der Impfung. Durch die 
Impfung induzierte Kreuzreaktivität für L1 und E7 ging über Speziesgrenzen hinaus, 
aber Kreuzneutralisation mit entfernt verwandten Typen wurde nicht beobachtet. 
Impfung mit chimären VLP induzierte auch Antikörper gegen andere frühe HPV-
Proteine, was darauf hinweist, dass diese Proteine aus den Läsionen freigesetzt 
wurden im Rahmen der immunologischen Impfantwort. 
Zusammengefaßt zeigt diese Dissertation, dass bakteriell exprimierte GST-
Fusionsproteine gut brauchbare Antigene sind für die HPV-Serologie und nützliche 
Werkzeuge zur Definition und Charakterisierung komplexer Muster 
konformationeller und linearer kreuz-reaktiver Epitope sind. 
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1. Introduction 
 
1.1 Human Papillomaviruses (HPV) 
 
Papillomaviruses (family Papillomaviridea) are widespread small double-stranded DNA 
viruses that infect the squamous epithelial cells of the skin and mucous membranes of human 
and a variety of animals and induce hyperproliferative lesions, e.g. warts. They are highly 
species- and tissue-specific viruses. 
Certain types of human papillomaviruses (HPV) have recently been linked etiologically to 
cervical abnormalities including precancers, cervical cancer, warts, and recurrent respiratory 
papillomatosis. They are also found to be associated with subgroups of other malignancies 
such as squamous cell carcinomas of the anus, vulva, vagina, penis, and head and neck. 
Based on the frequency with which these types are found in cancers and precursor lesions, 
HPV can be divided into high-risk, intermediate-risk, and low-risk subtypes. Low-risk 
subtypes, such as HPV11 and 6 are associated with benign genital warts (condyloma 
acuminate), low-grade or benign cervical lesions (Schiffman & Castle, 2003). Intermediate 
and high-risk subtypes are associated with cervical dysplasia and invasive carcinoma. 
 
1.2 Capsid structure 
 
HPV are small, non-enveloped icosahedral particles ~52-55nm diameter. There are 72 
capsomers (60 hexameric + 12 pentameric) arranged on a T = 7 lattice. The icosahedral HPV 
capsid consists of 360 copies of L1 major structural protein (55 kDa) and approximately 12 
copies of L2 (75 kDa) minor structural protein (Kieback & Muller, 2006) (Figure 1).  
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1.3 HPV genome organization and major key proteins 
 
Human papillomaviruses (HPV) contain a single molecule of double-stranded circular DNA 
of approximately 8 kb (Fig. 2) associated with cellular histones to form a chromatin-like 
substance (Modis et al., 2002). HPV 16 genome is described here as a representative type, 
however, some differences may occur in other types, e.g the genome might slightly vary in 
size between different HPV types. HPV 16 genome can be divided into three regions, the 
noncoding long control region (LCR), or the upper regulatory region (URR), and the early 
(E) and late (L) gene region (protein encoding). The long control region of 400 to 1,000 bp 
contains cis-acting regulatory sequences and overlapping binding sites for many different 
transcriptional activators and repressors, including activating protein 1 (AP 1), and nuclear 
factor 1 (NF-I). The LCR regulates transcription from the early and late regions, and 
therefore controls the production of viral proteins and particles. The early region (about 4.5 
KDa) is downstream of the LCR and contains six open reading frames, E1, E2 and E4—E7, 
and is involved in viral replication, transcription and cellular transformation. The late region 
(2.5 KDa) encodes the viral major and minor capsid proteins, L1 and L2 respectively. Both 
proteins are required late in the viral life cycle to encapsulate the virus (zur Hausen, 1996).  
 
A 
Figure 1. Structure of HPV particle.  
A) A single capsomere consists of 5 copies of L1 
structural protein. 72 capsomeres with one copy of viral 
DNA and 12 L2 copies combine to form the infectious 
virus particle. 
B) Electron microscopic picture of Papillomavirus 
particles. Source: 
www.merckmedicus.com/.../hpvd/images/figure2.jpg    
B 
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HPV early proteins 
 
The HPV early (E) region in general encodes six open reading frames: 
E1 protein plays a role in initiating the replication of the viral DNA, maintenance of the viral 
episome as it encodes DNA-binding protein (Scheffner et al., 1994). It is also essential in 
control of gene transcription. It is highly conserved among papillomaviruses. 
 
E2 protein is a DNA-binding protein and together with E1 is required for initiation of viral 
genome replication. It plays an important role in viral genome segregation during cell 
division by tethering the viral genome to the mitotic chromosomes (Skiadopoulos & 
McBride, 1998). It functions also in regulating the viral gene expression through a specific 
interaction with the early promoter found in the upstream regulatory region (Doorbar, 2006).  
 
E6 is a 16- to 19-KDa protein. It contains four Cys-X-X-Cys motifs which mediate the 
formation of two zinc finger structures (McMurray et al., 2001). It binds to the p53 tumor 
suppressor protein and causes its destruction by the ubiquitin proteolysis pathway. This 
results in a loss of p53-dependent functions including G1 arrest and apoptosis. E6 is also a 
key oncoprotein in the development of cervical cancers as it compromises the effectiveness 
Figure 2: Structure of HPV16 genome  
Source: http://www.baclesse.fr/cours/fondamentale/7-
carcino-virale/Virale-6.htm 
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of the cellular DNA damage response and allows the accumulation of secondary mutations to 
go unchecked.  
 
E7 is a 10- to 14-KDa phosphoprotein that has transforming activity and regulatory functions. 
It interacts with and degrades RB, which releases the transcription factor E2F from RB. The 
resulting high E2F activity might lead to apoptosis in E7-expressing cells (zur Hausen, 1996). 
E7 of high risk types bind additionally with other Rb-related proteins, such as p107, p130, 
and with the protein kinase p33cdk2. It also stimulates the S-phase genes, cyclin A and cyclin 
E and induces aneuploidy of the E7-expressing cells by inducing centriole amplification, 
which may contribute to tumorgenesis (Dyson et al., 1989; Tommasino et al., 1993). In high-
grade cervical intra-epithelial neoplasia (CIN II/III) and cervical cancer, E7 and E6 are 
constitutively expressed in all layers of the infected epithelium.  
Both E6 and E7 are expressed in addition to the other early proteins in the lower spinous 
layers, and they are considered as the predominant transforming proteins and therefore are 
potential targets for activated T cells in the development of strategies for immune responses. 
 
E5 protein is a hydrophobic trans-membrane protein that resides predominantly in the ER 
(endoplasmic reticulum). It interacts with and upregulates the trans-membrane domain of the 
EGFR (epidermal growth factor receptor) (Crusius et al., 1997; Crusius et al., 1998). E5 
protein seems to be not necessary for the maintenance of the viral transformed phenotype as 
it is generally not detected in cervical cancers after viral genome integration (Munger et al., 
2004); however, it has been shown to prevent apoptosis following DNA damage. 
 
E4 protein seems to be one of the viral tools that contribute to the viral release process by 
binding and inducing the collapse of the cytokeratin network of the infected cells (Doorbar et 
al., 1991; zur Hausen, 1996). E4 accumulates in the cell at the time of viral genome 
amplification, and its loss has been shown to disrupt late events in a number of experimental 
systems (Nakahara et al., 2005; Peh et al., 2004; Wilson et al., 2005). It is located on the 
early region of the genome, but its expression pattern is more similar to the late proteins. 
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HPV late proteins 
 
The HPV genome encodes two structural proteins, L1 and L2, which are expressed only late 
in infection in the differentiating keratinocytes (Stoler, 2000). 
L1 is the major capsid protein in the virus particle. It has a molecular weight of 
approximately 55 KDa and represents approximately 80% of the total viral proteins. 
Additionally it is the most highly conserved protein among all the papillomavirus proteins (de 
Villiers et al., 2004). Serologically, neutralizing epitopes were found to locate on the exposed 
surface of L1 (Dillner, 1999).  L1 has the intrinsic capacity to self-assemble into virus-like 
particles (VLP) (Hagensee et al., 1994; Kirnbauer et al., 1994; Zhou et al., 1991). 
 
L2 is the minor capsid protein and it is thought that a single L2 molecule may be present in 
the centre of the pentavalent capsomeres at the virion vertices (Modis et al., 2002; Trus et al., 
1997). L2 has a molecular size of approximately 72 KDa. Synthesis of L2 is initiated prior to 
synthesis of L1 in the terminally differentiating keratinocytes (Florin et al., 2002). In the 
capsid, L2 may have a variety of functions possibly including binding of a secondary 
receptor, nuclear localization, or binding to the viral genome (Day et al., 1998; Zhou et al., 
1994). It is essential for the infectivity of pseudovirions and probably also virions, but its 
exact role in papillomavirus infection is still unclear.  
 
1.4 Classification 
 
Papillomaviruses are very diverse and they have a high degree of species specificity as there 
are no known examples of natural transmission of HPV to other species.  
Papillomaviruses also display a marked degree of cellular tropism. Specific viral types appear 
to have a preference for either cutaneous or mucosal types.  
So far, more than 100 HPV types have been fully characterized by cloning and complete 
sequencing of their genomes. Classification of HPV is based on the L1 open reading frame 
nucleotide sequence (Figure 3). HPV of the same genus show at least 60% sequence identity, 
those of the same species at least 70%, those of the same type at least 90%, those of the same 
subtype at least 98% and those of the same variant >98% (de Villiers et al., 2004). The two 
main HPV genera are the alpha and beta papillomaviruses, encompassing approximately 90% 
of currently characterized HPVs. HPV of the genus alpha (12 species) mostly infect 
anogenital and oral mucosa, however, it also includes three species with cutaneous viruses 
such as HPV 2, which cause common skin warts and benign genital lesions (de Villiers et al., 
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2004). Beta papillomaviruses are typically associated with inapparent cutaneous infections, 
but in immunocompromised individuals and in patients suffering from the inherited disease 
EV (epidermodysplasia verruciformis), these viruses are discussed to become associated with 
the development of non-melanoma skin cancer (Harwood & Proby, 2002; Pfister, 2003). 
The remaining HPV come from three genera (Gamma, Mu and Nu) and generally cause 
cutaneous papillomas and verrucas that do not progress to cancer. 
Approximately 15 high-risk types are known (most frequent types 16 and 18) (Munoz et al., 
2003) and they belong to genus alpha, species 5, 6, 7, 9 and 11 (Bosch & de Sanjose, 2003; 
Clifford et al., 2003; zur Hausen, 2002). HPV16 is the most prevalent high-risk HPV in the 
general population, and is responsible for approx. 50% of all cervical cancers. 
                                            
                
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Phylogenetic tree of 118 papillomavirus types based on 
homology of L1 ORF. Modified from de Villiers et al 2004. 
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1.5 HPV life-cycle and pathogenecity 
 
Viral infection is exclusively restricted to the basal keratinocytes, however, high level 
expression of viral proteins and viral assembly occur only in differentiating keratinocytes in 
the stratum spinosum and granulosum of squamous epithelium (Figure 4) (Peh et al., 2002; 
Woodman et al., 2007). The viral life-cycle has both a non-productive and a productive stage 
(Figure 4). The none-productive stage starts when the virus particle penetrates the epithelium 
via a microabrasion and infects the epithelial stem cells which are located in the basal 
epithelial cell layer. There, the virus establishes its DNA in the host cell episomally and 
maintain the genome copy number (50 to 100 copies per cell) (Chow & Broker, 1994; Durst 
et al., 1985; McMurray et al., 2001) by the help of the cellular DNA replication machinery 
and the expression of the viral early proteins E1 and E2. 
When the infected cells undergo division, a subset of the daughter cells remain part of the 
basal epithelium, while the other cells leave the basement membrane to stratify and 
differentiate. During this process, the productive stage is started, as the virus amplifies its 
genome to a higher copy number, express the late genes, encapsidate the genome and finally 
the new viral progeny is produced.   
In the majority of advanced lesions and invasive tumors, HPV is integrated into the host 
genome. E6 and E7 transcripts from integrated HPV genomes have increased stability 
compared with episomally derived viral mRNA, and there is an increased expression in more 
severe lesions and cancers. Following integration, continued E6 and E7 activity prolongs the 
cell cycle, leading to the loss of effective DNA repair mechanisms providing the opportunity 
for the accumulation of genetic changes in a multistep process resulting in the development 
of cancer. E6 and E7 are independently able to immortalize various human cell types in tissue 
culture, but efficiency is increased when they are expressed together. 
When the vegetative virus replication is initiated, E6 and E7 proteins bring the differentiated 
cells back into S-phase. This leads to hyperprolifiration of cells and thus to the typical 
macroscopic features of a papillomavirus infection, i.e. the formation of a wart. 
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The replication cycle (the time from infection to release of virus) usually takes a long time; 
about 3 weeks; since this is the time the basal keratinocyte needs to complete differentiation 
and desquamate. The time between infection and the appearance of lesion varied from weeks 
to months (Koutsky, 1997; Oriel, 1971; Schneider & Koutsky, 1992).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal cervix Squamous Intraepithelial lesion Invasive cancer 
Figure 4. HPV life-cycle and pathogenesis. Human papillomavirus (HPV) is thought 
to access the basal cells through micro-abrasions in the cervical epithelium. The early 
HPV genes E1, E2, E4, E5, E6 and E7 are expressed after the infection, and the viral 
DNA replicates from episomal DNA. In the upper layers of epithelium the viral genome 
is replicated further, and the late genes L1 and L2, and E4 are expressed. L1 and L2 
encapsidate the viral genomes to form progeny virions in the nucleus which can then 
initiate a new infection. The progression of untreated lesions to microinvasive and 
invasive cancer is associated with the integration of the HPV genome into the host 
chromosomes, with associated loss or disruption of E2, and subsequent upregulation of 
E6 and E7 oncogene expression. Modified from Woodman et al, 2007.  
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1. 6 HPV and human diseases  
 
Several cancers are so far partially attributed to the consequences of chronic viral or bacterial 
infections. Examples are Helicobacter pylori (gastric cancer), Epstein-Barr virus (EBV) 
(Burkitt’s lymphoma, nasopharyngeal carcinoma and Hodgkin’s disease), Hepatitis B and C 
(hepatocellular carcinoma), human herpes virus type 8 (Kaposi’s sarcoma) (zur Hausen, 
1999).   
Most HPV such as types 1, 2, 3 or 4 preferentially infect cutaneous skin and usually cause 
only benign disease (e.g. plantar, common warts), HPV -5, -8 and related types cause skin 
lesions in the rare genetic disease epidermodysplasia verruciformis, which in 40% of the 
patients progress to cancer (Akgul et al., 2006; Favre et al., 1998a; Favre et al., 1998b). Low-
risk mucosal HPV types 6 and 11 cause benign ano-genital condylomata acuminata, upper 
aerodigestive tract papillomas (most notably laryngeal papillomas), and conjunctival and ear 
canal papillomas (zur Hausen, 2002).  
Infection by certain high-risk HPV types is strongly correlated with the development of 
malignant tumors as their DNA is detected in more than 99% of cervical cancers. World wide 
there are about 500.000 new cases each year commonly in 30-50-years old women and about 
275.000 cervical cancer deaths, making it the second most common cause of cancer deaths in 
women (Parkin et al., 2005). HPV 16 DNA is detected in >50% of all cervical tumors 
(Clifford et al., 2003; Munoz et al., 2003). The next most common HPV type associated with 
cancer (found in 10-14% of all cervical carcinomas) is HPV 18 followed by HPV types 31 
and 45 which cause an additional 10 % of all cases (Bosch et al., 2002). About 80% of 
cervical cancers occur in less-developed countries. This high proportion is mainly due to the 
lack of well-organized screening programs.  
HPV infections are more frequent in immunocompromised individuals such as organ-
transplant recipients (Sillman et al., 1997) or HIV-infected patients (Ferenczy et al., 2003; 
Palefsky, 2007). As only a small fraction of women infected with oncogenic HPV types will 
eventually progress to high-grade squamous interepithelial lesions (HSIL) and cervical 
cancer, additional risk factors including high parity, long-term use of oral contraceptives, 
smoking, and co-infection with other sexually transmitted agents are the most consistently 
identified environmental co-factors and are likely to influence the risk of progression from 
cervical HPV infection to HSIL and invasive cervical cancer. 
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1.7 Immune response to HPV   
 
During the natural course of HPV infection, papillomaviruses in general are not very 
immunogenic and the natural immune response is very weak in comparison to most of other 
viral infections (Frazer, 1996). HPV persistence suggests that the virus uses several 
mechanisms that function to direct the host immune response away from the virus: 
1. There is no sign of inflammation within a wart due to the inability of the keratinocytes to 
function as antigen-presenting cells and therefore there is no obvious danger signal to alert 
the immune system.  
2. The immune response against L1 and L2 proteins is slow to appear and does not occur in 
all infected individuals as the virus delays the production of these immunogenic capsid 
proteins until the skin cells have terminally differentiated into squamous epithelium which is 
sloughed off and not accessible to the immune cells.  
3. The viral early proteins E6 and E7 that mediate cell proliferation in the lower epithelial 
layers are expressed at very low levels.  
4. Expressed E6 protein regulates E-cadherin expression and Langerhans cell density 
(Matthews et al., 2003). 
5. Expression of E5 in the basal layers of the epithelium early in infection, down-regulates 
MHC class I expression resulting in avoidance of attach by effector cytotoxic T-lymphocytes 
(CTL) (Zhang et al., 2003).  
6. Both E7 and E6 can down-regulate IFN-dependent innate immunity (Barnard et al., 2000). 
7. The infection does not cause a lytic infection as the infectious particles are produced only 
in the upper epithelial layers in cells that are eventually lost from the epithelial surface at the 
end of their life span.  
 
Humoral immune response 
Natural HPV infection leads to induction of slow and modest but measurable serum antibody 
response in most but not all (50-70%) of the infected individuals (Carter et al., 1995; Carter 
et al., 2000; Dillner, 1999). These antibodies are specific for the major capsid protein L1 and 
are suggested to be directed against conformational epitopes; neutralize the virus. 
Conformational epitopes are operationally defined as those displayed on the outer surface of 
the intact virus particle, VLP and capsomeres and are destroyed by heat/alkali denaturation. 
Epitopes presented by small synthetic peptides and denatured VLP are defined as linear 
epitopes, these can also be present on intact VLP preparations either because they are 
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surface-exposed on capsids or because the VLP preparation also contains some denatured L1. 
Neutralizing epitopes have also been identified in the L1 major capsid protein (Christensen et 
al., 1994; Giroglou et al., 2001; Rose et al., 1998; White et al., 1998; White et al., 1999). 
Monoclonal antibodies (mAb) generated against VLP of different HPV types including 6, 11, 
16, 18, 31, 33, 35, and 45 (Christensen et al., 1996a; Christensen et al., 1996b; Combita et 
al., 2002; Ludmerer et al., 2000) have been used in identifying  these different epitope 
displayed by HPV capsid.  
The presence of these L1-specific antibodies is long-lasting; however, it does not contribute 
to the clearance of the infection (Shah et al., 1997). In animal experiments, these antibodies 
are able to protect animals against further infection with the same virus type (Kreider & 
Bartlett, 1981; Suzich et al., 1995).      
HPV-L1 specific antibodies are considered markers for past or current infection as they are 
more frequently detected in patients with persistent infections or precancerous lesions (Carter 
et al., 2000; Nonnenmacher et al., 1995). On the other hand, antibodies specific for early 
proteins (mainly E6 and E7 oncogens) are only associated with the onset of cervical 
carcinoma (Lehtinen et al., 2003; Meschede et al., 1998; Silins et al., 2002; Zumbach et al., 
2000). Regarding the other early proteins (E1, E2 and E4), limited data is available on 
responses in patients with HPV-associated diseases. 
 
Cellular immune response 
In this kind of immune response, the key players are T-cells (T-helper and cytotoxic T-cells). 
It can be found both in patients with and without HPV-associated lesions. Recognition of 
HPV-infected cells and stimulation of T-helper 1 (Th1) cells (which elicit the production of 
CTL) is mediated by the presence of dendritic cells or Langerhans cells in the cervical 
epithelium (Niedergang et al., 2004). The stimulated cytotoxic effector cells can attach the 
infected cells resulting in clearance of the naturally acquired HPV infection (Stern, 2004) 
and/or regression of existing HPV-associated lesions.  
 
Cross-reactions between different HPV types 
Antibodies formed after infection with one-type of HPV usually do not bind to other types of 
HPV. Additionally, prior infection with one HPV type does not appear to prevent infection 
with another related type, which might suggest that generally different types of HPV 
correspond to different serotypes, and that the immune response to one type of HPV does not 
protect against other types of HPV (Thomas et al., 2000). However, HPV 6 and 11 are one 
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exception as they contain shared epitopes on their intact capsids (>92% amino acid identity in 
L1); antibodies formed after infection with HPV 11 may partially protect against infection 
with HPV 6 and vice versa.  
During the sexually active period of life, infection with more than one HPV type can happen 
and therefore co-occurrence of several type-specific serum antibodies is a common 
phenomenon. The very long persistence of HPV-specific serum antibodies after HPV DNA 
has been cleared and the common mode of transmission of these viruses could explain this 
phenomenon (Konya & Dillner, 2001). On the other hand, cross-reactions due to shared 
epitopes between different HPV types are also often observed, e.g, HPV 6 and 11 or HPV 18 
and 45. Based on this, a major serological problem is the difficulty in distinguishing type-
specific antibody response to multiple HPV types from cross-reactivity (Table 1).  
 
Detailed study of the immune response and its correlation with the pathogenesis of HPV-
associated lesions is very important for a successful vaccine development that helps in 
prevention of new viral infection as well as in treatment of already occurred HPV-associated 
lesions. 
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Table 1. Patterns of serological reactivity (Luminex-based GST-L1 antibody assay) of human 
sera to different HPV types. Colored numbers are positive signals (>300 MFI). Reactivity to more 
than one type is often observed.   
 
 
1.8 Vaccines against HPV infections 
Vaccines against HPV have been or are currently developed from one side in order to prevent 
infection (protection) and on the other side to cure the already infected women (therapy). In 
this context, the induction of immunity to HPV proteins L1 and to E6 and E7, respectively, 
plays a crucial role in the strategy against HPV infection and subsequent HPV-related 
precancerous and cancerous lesions. L1 protein is used to elicit a strong humoral immune 
response from the host making it a good target for protective vaccination. On the other hand, 
the presence of E6 and E7 throughout the precancerous and cancerous stages makes them 
ideal targets for immune therapeutic vaccine development. 
 
 
Genus Alpha
Species 9 7 10
Type 16 33 35 52 58 18 45 6b 
Seronegative 14 54 17 22 11 80 0 148
1 131 0 39 0 93 52 271
0 0 0 0 0 0 0 297
0 57 0 50 0 65 12 179
28 0 0 38 0 0 108 65
Mono-reactive 3521 143 94 173 8 286 74 190
0 120 178 57 192 2546 0 204
0 172 8 0 0 37 31 2271
0 55 4051 131 197 33 12 269
111 116 0 0 985 175 7 203
0 408 0 0 0 0 0 217
43 109 14 74 1105 86 35 1065
Oligo-reactive 2403 46 0 18 0 151 0 2079
136 196 0 0 79 601 403 643
136 196 0 0 79 601 403 643
86 59 99 38 1007 43 0 616
7 106 1229 64 15 57 31 653
754 312 97 123 538 496 110 845
Multiple positive 1382 1019 840 266 595 2411 1151 1557
8622 2032 1792 1152 1395 3541 2290 1739
2274 845 593 199 64 1484 1695 593
1442 1209 1236 538 208 331 197 430
0 1350 1129 1644 1319 149 0 348
 15 
Prophylactic vaccines 
They are vaccines that target HPV capsid proteins and elicit antigenic reaction from the host 
through the humoral immune response by inducing virus-neutralizing antibodies. A 
successful vaccine should immunologically mimic the infections it aims to prevent and prime 
the adaptive immune system to recall specific effector functions to any future encounters with 
the infectious agents.  
 
Therapeutic vaccines 
Therapeutic vaccines target those individuals who are already infected by high-risk 
papillomaviruses and who may or may not have developed clinical signs of the infection. For 
a successful vaccine, the chosen target antigens should be expressed in every infected cell 
and the vaccine should promote regression of HPV-associated lesions by the induction of 
cellular immune responses. These responses include, CD8+ CTL, and cytokines with direct 
(IFN-α and IFN-γ) or indirect (interleukin-1, IL-1 or IL-2) effects on virus-infected cells 
(Frazer, 2004). E6 and E7 oncoproteins expressed in cervical cancer cells have been found to 
induce CTL responses in infected patients and specific antibodies in a proportion of patients 
with cervical carcinomas, so they are considered as the most suitable prime target antigens 
for immune therapy. Additional targets are the E1 and E2 proteins associated with viral 
replication/transcription (Jansen & Shaw, 2004). 
 
Clinical vaccination trials 
Several pre-clinical vaccination studies in animal models have been conducted. However, 
using the inactivated virions (when available, as there is no easy source for them) as vaccines 
was tricky and not suitable to be used in humans due to the possibility of introducing the viral 
oncogenes to the recipient’s body. Alternatively, VLP were used as vaccines. These trials 
showed that VLP were protective both against cutaneous warts induced by the cottontail 
rabbit papillomavirus (CRPV) (Breitburd et al., 1995; Jansen et al., 1995) and also against 
mucosal warts induced by the canine oral papilloma virus (COPV) (Suzich et al., 1995) and 
the oral bovine papilloma virus 4 (BPV 4) (Kirnbauer et al., 1996). In these models, the 
vaccines used induced high-titers of serum-neutralizing antibodies and protected against 
experimental challenge with the infectious virus.   
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In humans, several randomized clinical vaccination studies based on L1-VLP of the high 
and/or low risk HPV types have been completed and some are still ongoing. The first HPV 16 
VLP (Harro et al., 2001), HPV 11 VLP (Evans et al., 2001), HPV 16/11 (Fife et al., 2004) 
and HPV 18 (Ault et al., 2004) phase I vaccine trials showed that the vaccines were well 
tolerated and highly immunogenic even when administered without adjuvant and that the 
antibody titers in the immunized subjects was at least 40-folds higher than in natural 
infections. Several clinical phase II and III randomized placebo-controlled trials were also 
conducted. The vaccines used were either monovalent HPV 16 (Koutsky et al., 2002; Mao et 
al., 2006; Poland et al., 2005), bivalent HPV 16/18 (Harper et al., 2004; Harper et al., 2006), 
or quadrivalent HPV 16/18/6/11 VLP (Villa et al., 2005; Villa et al., 2006a). The vaccination 
results showed that these vaccines were well tolerated, highly immunogenic as they induced 
type-specific neutralizing antibodies, provided complete protection against persistent type-
specific infections and HPV associated diseases and induced long-term immunity for up to 
4.5 years (Harper et al., 2006; Villa et al., 2006b). Besides the induction of antibodies, these 
vaccines were able to induce L1-specific CD4+ and CD8+ T-cell responses and Th1 and Th2 
cytokines (Pinto et al., 2005). Two prophylactic vaccines are now commercially available, 
Glaxo Smith Kline’s (GSK) bivalent vaccine named CervarixTM and the Merck quadrivalent 
vaccine GardasilTM. Phase III trials of these two vaccines revealed that they were highly 
efficacious in preventing HPV 16/18 related CIN II/III and adenocarcinoma in situ (ASI) 
(Ault, 2007; FUTUREII, 2007; Garland et al., 2007; Paavonen et al., 2007) and high grad 
vulval and vaginal lesions associated with HPV 16 or HPV 18 infection (Joura et al., 2007).  
A successful control for HPV-associated lesions and cancer would be to develop a vaccine 
that has a prophylactic as well as therapeutic property; able to induce neutralizing antibodies 
and a T-cell mediated immune response. To this end, chimeric VLP (cVLP) were established 
as alternative to VLP. CVLP are generated by the fusion of E7 protein to L1 or L2 (Muller et 
al., 1997; Wakabayashi et al., 2002) and when used for immunization in mice, they were able 
to induce L1-specific and neutralizing antibodies, to elicit an E7-specific cellular immune 
response and to prevent the growth of E7-positive cells in mice (Greenstone et al., 1998; 
Nieland et al., 1999; Schafer et al., 1999). In vitro vaccination in human (using purified 
peripheral blood lymphocytes, PBL) revealed also the ability of the cVLP to trigger a specific 
T-cell immen response (Kaufmann et al., 2001). Results of a recently published randomized, 
double-blind, placebo-controlled phase I/II clinical vaccination trial with HPV16 L1/E7 
cVLP targeting patients with HPV 16 positive CIN II/III demonstrated an evidence for the 
safety of the vaccine and a non significant-trend for clinical efficacy. The trial showed that 
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the vaccine is able to induce L1 and E7 specific antibodies and also a cellular immune 
response (Kaufmann et al., 2007).   
 
 
1.9 HPV serology 
 
Serological assays are used to detect systematic immune response developed upon infection 
with HPV. However, the development of such assays faces some limitations including the 
large number of HPV types associated with different diseases and difficulties in isolating or 
producing sufficient quantities of infectious virions in cell cultures or in vivo. 
 
Developments of antigens used in serology 
Different antigens have been used so far in different established assays to overcome these 
limitations.  
 
1. VLP 
Different expression systems to over-express the L1 capsid protein and generation of VLP 
have been used including vaccinia virus (Hagensee et al., 1993), plasmid vectors (Pastrana et 
al., 2004) or baculovirus (Kirnbauer et al., 1992) in yeast (Sasagawa et al., 1995), 
mammalian, or insect cells (Le Cann et al., 1994), respectively. 
VLP mimic the natural virions morphologically and immunologically and they display 
immunodominant conformational epitopes (Christensen et al., 1996a; Christensen et al., 
1996b; Christensen et al., 2001) and are able to generate high titers of type-specific 
neutralizing antibodies (Le Cann et al., 1994; Schiller & Lowy, 1996).  
 
2. Fusion proteins 
It is possible to achieve a favourable yield of recombinant proteins in E.coli, but obtaining the 
protein in a soluble, biologically active form was a major challenge so far. In the meantime, 
fusion proteins have become of great importance in the biological researches with a wide 
range of applications. Examples of these worth to use fusion proteins are, thioredoxin (TRX) 
(LaVallie et al., 1993), Protein A (Samuelsson et al., 1994), ubiquitin (Power et al., 1990), 
DsbA (Zhang et al., 1998), glutathione S-transferase (GST) (Nygren et al., 1994) and 
maltose-binding protein (MBP) (Pryor & Leiting, 1997). In the context of this thesis, the last 
two fusion proteins are of interest.    
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Glutathione S-Transferase (GST) 
GST (26 KDa) is derived from the parasitic helminth protein of Schistosoma japonicum. 
Recombinant expressed GST fusion proteins can be expressed in bacteria (Smith & Johnson, 
1988), yeast (Lu et al., 1997), mammalian cells (Rudert et al., 1996) or baculovirus-infected 
insect cells (Beekman et al., 1994). They could be purified from crude lysates by affinity 
chromatography on immobilized glutathione.  
 
Maltose-binding proteins (MBP) 
MBP is a periplasmic protein (40 KDa) encoded by the malE gene of E.coli K12 (Duplay et 
al 1988). It constitutes a part of the maltose/maltodextrin system of the bacteria which is 
responsible for the uptake and efficient catabolism of maltodextrins and used for the secretion 
of proteins into the periplasm (Blondel & Bedouelle, 1990). MBP can facilitate the solubility 
of over expressed fusion proteins in bacteria, especially eukaryotic proteins (Sachdev & 
Chirgwin, 1998). One-step purification of the MBP fused proteins is based on the strong 
affinity of MBP to cross-linked amylose. The MBP system is widely used in combination 
with a small affinity tag (Podmore & Reynolds, 2002).  
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Serological assays 
Recent developments in HPV serological techniques include capture assays using bacterially 
expressed recombinant viral proteins (Sehr et al., 2001; Sehr et al., 2002) and the 
introduction of fluorescent bead-based technologies (Luminex) (Waterboer et al., 2005; 
Waterboer et al., 2006) which resulted in increased sensitivity and specificity of HPV 
antibody detection. 
In this PhD work the following assays were applied. The detailed step by step description is 
explained in the individual contributions as cited below.    
 
1. VLP-capture ELISA 
 
So far, VLP-based ELISA is the standard technique to detect HPV L1 antibodies. It was first 
developed to screen for antibodies to HPV1 (Carter et al., 1993) and HPV16 (Kirnbauer et 
al., 1994). The assay was then applied for many other HPV types including Canine oral PV 
(CoPV) (Suzich et al., 1995), Cottontail rabbit PV (CRPV) and bovine PV 1 (BPV 1) 
(Christensen et al., 1996a), BPV4 (Kirnbauer et al., 1996), HPV45 (Touze et al., 1996), 
HPV6 and 11 (Touze et al., 1998), HPV5 (Favre et al., 1998b), HPV8 (Bouwes Bavinck et 
al., 2000), HPV31, 33, 35, 18, 39 (Giroglou et al., 2001), HPV59 (Combita et al., 2002) and 
HPV15, 20 and 24 (Feltkamp et al., 2003). The critical issue for VLP-based ELISA is the 
complexity of VLP production and the time consuming long purification procedure. 
Therefore, several attempts have been made to improve the specificity of the VLP-based 
antibody assays by capturing correctly folded antigen through mAb recognizing 
conformational L1 epitopes (Carter & Galloway, 1997; Wang et al., 1997), through heparin 
(Wang X, 2005) or by competition assays, in which binding of a mAb to a conformational 
VLP epitope is inhibited by a test serum (Dias et al., 2005; Palker et al., 2001).  
 
2. Glutathione-S-transferase capture ELISA 
 
In this assay, recombinant proteins are over-expressed as GST fusion proteins in E.coli and 
affinity-purified directly on glutathione cross-linked to casein (GC) as capture protein on the 
ELISA plates (Sehr et al., 2001; Sehr et al., 2002). Fusion with the GST moiety occurs via 
the N-terminus of the viral over-expressed protein (Wilce & Parker, 1994), therefore the 
fused proteins are thought to present in a native conformation. The bound full-length fusion-
protein can be monitored via an amino acid sequence (KPPTPPPEPET) from the terminal 
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undecapeptide of the SV40 large T-antigen (tag) and fused here to the C-terminus of the HPV 
protein (Figure 5A). GST-capture ELISA is a very sensitive and highly specific and has been 
applied to a variety of antigens. 
Both ELISA formats (using VLP or GST-fusion protein as antigens) were used in the 1st 
contribution in a direct comparison to analyze and characterize the different epitope defined 
by 92 monoclonal antibodies.   
 
3. Mutiplex serology (Luminex) 
 
Seroepidemiological studies on prevalence and disease association with HPV require a 
method that allows a simultaneous analysis of large number of sera to many different 
antigens under the same working condition. Introduction of fluorescent bead-based 
technology (Luminex, Multiplex serology) (Waterboer et al., 2005; Waterboer et al., 2006) 
resulted in increased sensitivity and specificity of HPV antibody detection systems.  The 
technology is based on using polystyrene beads (about 5.6 µm in diameter) filled with two 
different fluorescent dyes in different ratios (Figure 5B). There are 100 sets of these beads 
distinguished by their internal colour and could be loaded with different antigens. To be able 
to use GST-fusion protein in this assay, the carboxyl groups of the beads are coupled to the 
terminal amines of the Glutathione-casein. Incubation of the GC-beads with the antigens, sera 
and the detection reagents can be done in special 96-wells washing microtiter plates with 
filter bottoms (Millipore). The Luminex analyzer consists of a needle in which the loaded 
beads are lined up prior passing through the detection chamber, allowing the single particle to 
be measured directly. In the detection chamber, two lasers are used; the red laser is 
responsible for the classification of the beads according to their colours and the green laser 
analyzes the binding of the antibodies by exciting the reporter fluorescent label bound to each 
bead.  
Multiplex serology is advantageous over the classical capture ELISA as the assay allows for 
screening of antibodies against up to 100 different antigens in a single sample using only a 
very little amount of the test serum (2µl/well). Luminex assay seems to be also more 
sensitive and specific in comparison to ELISA; it can detect the very weak ELISA signals but 
with less undesired background. 
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Figure 5: Schematic illustration for A) GST-capture ELISA , modified from Sehr et al 2001 
and B) Luminex system, modified from Waterboer et al 2005. 
 
This system has been used in the 3rd contribution to analyze the humoral immune response 
in HPV 16 L1/E7 cVLP vaccination study.  
 
4. HPV 16 antibody blocking assay 
 
So far, VLP-based and GST-L1-based ELISA have been used successfully in large HPV 
epidemiological studies (Dillner, 1999), however, false positive cross-reactive signals might 
be obtained. These responses could be due to the fact that incorrectly folded VLP present in 
the antigen preparation used, expose cross-reactive epitopes that might compromise the type-
specificity of the VLP-based assay (Wang et al., 1997). On the other hand, GST-L1 fusion 
proteins were also found to present also the conformational and neutralizing epitopes as well 
as the linear (denatured) epitopes (Yuan et al., 2001) which are thought to be responsible for 
cross-reactivity signals.  The antibody blocking assay described here, based on soluble MBP-
capsid protein fusions. It was initially developed for HPV L1 proteins to find out if soluble 
L1 protein of one HPV type specifically blocks cross-reactivity to another HPV type. 
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5. Neutralization assay 
 
Neutralizing epitopes have been identified in the HPV L1 major capsid protein (Christensen 
et al., 1994; Giroglou et al., 2001; Rose et al., 1998; White et al., 1998; White et al., 1999). 
So far, most of the serological analyses of responses to natural HPV infection relied on assays 
(such as ELISA) that are surrogates for neutralization (Dillner 1999), or antibody 
displacement assays (Opalka et al., 2003; Yeager et al., 2000). The problem of these assays is 
the fact that the immunodominant neutralization epitopes of HPV are genotype-specific. In 
ELISA, non-neutralizing and cross-genotype reactive antibodies might also be detected. 
Generally, HPV neutralization assays are troublesome and mostly lack sufficient sensitivity 
to reliably detect serum-neutralizing antibodies following natural infection (unpublished 
data). Many alternative systems were explored  to develop an applicable HPV neutralization 
assay using athymic mouse xenografts  (Kreider et al., 1987), raft culture systems (Meyers & 
Laimins, 1994) or producing infectious HPV pseudovirions in vitro (Roden et al., 1996; 
Touze & Coursaget, 1998; Unckell et al., 1997). The most recent in vitro neutralization assay 
is based on pseudovirions carrying a secreted alkaline phosphatase (SEAP) reporter gene 
(Buck et al., 2005; Pastrana et al., 2004). In this assay, the pseudovirion production main 
strategy is based on maximizing the production of the two capsid proteins L1 and L2 together 
with a target reporter plasmid in mammalian cells. L1 and L2 genes (normally have very low 
expression levels in cultured mammalian cells) with extensive codon modification are used to 
overcome the negative regulatory features of the wild-type open reading frame (ORF) 
(Schwartz, 2000). To generate a high copy number of the reporter plasmid, an SV40 origin of 
replication is inserted into the target plasmid. The pseudovirion is produced in cells 
(adenovirus-transformed human embryonic kidney cell line, 293TT) transfected with SV40 
genome to express high levels of SV40 large T antigen (LT).  
Antibody-mediated pseudovirion neutralization is detected by a reduction in SEAP activity.  
The assay is explained in details in the 1st and 3rd contributions. 
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1.10 Aims of this thesis  
 
This thesis focused, on one hand on evaluating GST fusion proteins as antigens for 
serological assays and on the other hand on the analysis of HPV L1 epitopes recognized by 
experimentally and/or naturally induced antibodies. The three contributions included in this 
thesis had the following detailed specific aims.  
 
Contribution 1 
Using a panel of 92 monoclonal antibodies a study was conducted to: 
1. evaluate glutathione S-transferase (GST)-L1 fusion proteins as ELISA antigens for 
detecting capsid specific antibodies against alpha papillomaviruses. 
2. analyze the epitope repertoire (including type-specific, cross-reactive, conformational, 
linear and neutralizing epitopes) displayed by GST-L1 fusion proteins in comparison to VLP. 
 
Contribution 2 
The main objective was to establish a blocking assay based on soluble MBP fusion proteins 
to be able to differentiate between true infections and cross-reactions.   
 
Contribution 3 
The major aim of the analysis of a clinical cVLP (HPV 16 L1/E7) vaccination trial is to 
describe in detail the  vaccine-induced antibody response including: 
1. HPV 16L1 specific and neutralizing antibodies, 
2. HPV 16E7 specific antibodies, 
3. cross-reactive L1 and E7 antibodies and/or L1 cross-neutralizing antibodies.   
4. specific antibodies to HPV 16 early proteins E1, E2, E4 and E6. 
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2. Major findings 
 
2.1 Analysis of reactivity pattern of 92 monoclonal antibodies with 15 Human 
papillomavirus types 
 
In the first contribution (Reactivity patterns of 92 monoclonal antibodies with 15 human 
papillomavirus types) 92 VLP-specific monoclonal antibodies (mAb) generated against 9 
mucosal alpha papillomavirus types of species 7, 9, and 10 were used to evaluate GST-L1 
fusion proteins as ELISA antigens for detecting capsid-specific antibodies against alpha 
papillomaviruses in comparison to VLP, and to define which epitopes are type-specific or 
shared by several HPV types. L1 cross-reactivity patterns were determined with 15 different 
HPV types representing 6 species (alpha 1, 2, 4, 7, 9, and 10). Neutralization and cross-
neutralization properties with HPV types 6, 11, 16, 18 and 45 were also investigated.   
At 1:10 antibody dilution, eighty nine (97%) mAb were reactive with the specific HPV type 
used as immunogen (mAU≥110). The positive absorbance (A) values varied between 340 and 
2531 mAU (Figure 6). Although the remaining three mAb had estimated IgG concentration 
of >800 ng/ml, but they were either very weakly reactive (H6.C6 and H35.O3) or non-
reactive (H16.L4) at all with their specific HPV GST-L1 protein.  They all had A450<110 at 
1:90 dilution. 
Further specificity analyses included titration of the different mAb against their specific 
immunogens. This step allowed also determination of antibody titer which reflects the 
antibody concentration in the different preparations. The end point antibody titer was defined 
as the last dilution giving a signal equal or greater 110 mAU.  
All HPV 16 (except H16.L4) mAb were strongly reactive with GST-16L1 fusion protein and 
had Amax values above 1500 mAU. In tissue culture supernatants as antibody source, log end 
point titers varied from 2.2 to 6.2 (median 5.5). For the ascites monoclonal antibodies 
(H16.U4 and H16.V5), the log antibody titers were 6.8 and 7.3 respectively. When excluding 
H16.L4, the A1/2max values ranged from 823 (H16.E70) to 1209 (H16.5A) (mean 1043, 
median 1051, standard deviation (SD) 111) indicating about only 1.5 fold variation in the 
mAb concentration of the different supernatants. 
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Figure 6. Reactivity of monoclonal antibodies with GST-L1 fusion proteins of the respective 
HPV type used for immunization. 92 monoclonal antibodies generated against VLP of different 9 
HPV types were tested at 1:10 dilution in GST-L1 capture ELISA. Only one HPV 31 specific mAb 
was tested. 89 of the mAb reacted with the specific type used as immunogen. The dotted short lines 
represent the mean of mAU for each mAb group. The dashed long continuous line represent the cut-
off (110 mAU) used to define the reactive mAb.  
 
 
Similarly, mAB against HPV 31 , 18 , 45,  33, 11, 52 and 6 reacted strongly with GST-L1 of 
the respective type (at 1:10 Amax greater than 1500) with log end point titers between 2.2 and 
6.2 (median 4.8). The very high Amax and the sigmoidal titration curves with steep slopes 
indicated high affinity of these antibodies to their immunogens. 
The remaining six mAb (H33.E12, H35.Q8, H35.H9, H35.N6, H45.N5 and H18.A7) showed 
Amax values below 1500 for HPV 33 or 1100 mAU for the other types. Titers were between 
log 2.0 and log 4.3 (median 3.4) and the titration curves were flat. 
Reanalysis of the 28 HPV16 mAb at a different day revealed a high reproducibility of the 
assay (the coefficient of determination of the linear regression of the absorption values was 
R2=0.79). 
Of the 89 reactive mAb, 43 (48%) showed different inter- and /or intra-species cross-
reactivity patterns while the remaining 46 (52%) were mono-specific. All HPV 31, 35, and 52 
mAb were monotypic. The most frequent intra-species cross-reactivity among HPV 16 mAb 
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was with HPV 35 followed equally by HPV 31 and 58 and then HPV 33. HPV 52 was the 
least frequent cross-reactive type. The most frequent inter-species cross-reactive types were 
HPV 18 followed by HPV 45, 11, and 6. Reactivity to some alpha skin types was also 
observed. HPV 33 and 31 cross-reactive mAb, reacted only with closely related types (within 
α9 species), except one single cross-reaction for HPV 31 mAb with HPV 32. Most frequent 
cross-reactivity to skin HPV types were observed among HPV 18 cross-reactive mAb. On the 
other hand, cross-reactivity to the mucosal high-risk of   α9 or to the low-risk of α10 and α1 
were not frequent or were absent. For HPV 45 mAb, no inter-species cross-reactivity was 
observed. HPV 6 and 11 showed only rare and weak inter-species cross-reactions.  
 
Thirty four (46%) mAb neutralized pseudovirions of the specific HPV types used as 
immunogens (HPV 16, 18, 45, 6 and 11) with end point neutralization titers ranging from log 
1.7 to log 5.6. Only one cross-neutralizing mAb (H6.L12) has been reported. It neutralized 
HPV 6 as well as HPV 11 with only 0.3 fold difference in the log end point neutralization 
titer. 
 
Retesting of mAb with the same immunogen (VLP) used in their production showed that all 
HPV 16 mAb and the four generated against other HPV types but cross-reacted with HPV 16 
reacted in VLP-ELISA including H16.L4 which was non-reactive in GST-L1 ELISA and is 
known to detect an epitope located within the N-terminus of L1 (Christensen 1996 and 
unpublished). Generally, the titers in VLP-ELISA and GST-L1 ELISA were similar for 
neutralizing and for monospecific mAb, whereas the GST-L1 titers were higher than the 
VLP-ELISA titers for the non-neutralizing and for the cross-reactive mAb. For mAb 
recognizing linear/denatured epitopes, the GST-L1 to VLP titer ratios were higher than for 
mAb recognizing conformational epitopes.   
 
As a main objective of this study was to determine the epitope repertoire of GST-L1 fusion 
proteins, it was also interesting to characterize the type of epitopes recognized by the 
different mAb which reflects the epitope types that can be displayed by the GST-L1 fusion 
proteins. Epitope types of 28 mAb were defined in this study. Detection of epitope type was 
done by an immuno dot blot method using both native and denatured GST-L1 proteins. 
Conformational epitopes were defined when a signal appeared only under native and not 
denatured conditions whereas denatured or linear epitopes were defined when a signal 
appeared under either only denatured or both native and denatured conditions. The epitopes 
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of five mAb (H33.J3, H35.H9, H35.N6, H35.O3 and H18.A7) could not be defined as in at 
least two assays no signal under any conditions was detected even when using high 
concentration of the mAb. 
 
2.2 Establishment of HPV16 antibody blocking assay 
 
This assay was initially established to distinguish antibody response to multiple HPV types 
from cross-reactivity. 
HPV-16L1 protein fused to MBP was chosen, validated by ELISA and finally evaluated for 
suitability as a candidate to block epitopes displayed by GST-L1 fusion proteins used in 
serology. Anti-tag ELISA proved that MBP-16L1tag can react efficiently as well as GST-
16L1 does with HPV 16L1 specific antibodies of different sources (mouse and human). This 
indicated that fusing MBP to HPV16L1 had no adverse effect on protein folding and 
therefore on presentation of the different epitopes (see appendix 1, 2). 
Preabsorption of sera with MBP-16L1 lystae should specifically eliminate the specific 
reactivity to HPV 16 and any HPV 16L1-induced cross-reactivity to the very closely related 
HPV types of the same species (e.g HPV 31, 33, or 35) and also to other more distantly 
related types. Additionally, preabsorption with MBP-16L1 should not affect binding of 
antibodies specific for other types. 
The blocking activity of MBP-16L1 was titrated and the assay was evaluated using HPV-
reactive mAb as well as human sera.  
Pre-incubation of mAb or selected human sera with soluble MBP-16L1 fusion protein (2 
mg/ml, see appendix 3) efficiently blocked binding (>80% reduction in reactivity) of HPV16 
mono-specific and cross-reactive mAb/sera to GST-16L1. Reactivity of mAb/sera specific for 
other HPV (e.g HPV 6, 5 or 18) was unaffected (see appendix 3, 4).  
The first application for the established blocking assay was successfully done using a large 
panel of human sera. These sera showed multiple positive signals to multiple different closely 
or distantly related HPV types. This analysis was not done by ELISA but instead by bead-
based multiplex HPV serology as described earlier in section (2.3).  
Pre-incubation of the sera with MBP-16L1 blocked their reactivity to GST-16L1 almost 
completely. Positive reactions for HPV types closely related to HPV16 e.g. HPV 31 and 35 
were either completely or partially blocked. In case of HPV 31, 66% of the cross-reactions 
were completely blocked, while only 8% of the specific reactions were partially blocked 
(>50% reduction in MFI values). A similar picture was obtained for HPV 35 (60% 
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completely and 18% partially blocked). Sera showing positive signals to HPV types less 
strongly related to HPV16 (e. g HPV 6) retained their reactivities as only about 20% of the 
reactions were either completely or partially blocked.  
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Figure 7 (continued). Soluble MBP-HPV16L1 fusion protein blocks human HPV 16L1 (A) mono-
specific and cross-reactive antibodies but not (B) HPV 6, (C) 35 or (D) 31 specific antibodies. Results 
are shown in Median Fluorescence Intensity (MFI) values. 
 
The assay was successfully extended to HPV 6. MBP-6L1 blocking assay was applied to 
children sera of a Finnish HPV family study. The aim of this study is to investigate whether a 
previously observed HPV 6 and 11 responses in children in age of 6 month or older are type 
specific or are only due to cross-reaction with a non HPV infection.  The preliminary data 
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suggested that these detected antibodies are different from the maternal antibodies 
transmitted to the children from their mothers. (T. Enkirch, Diploma thesis 2007). 
 
In another application, the developed blocking assay principle was extended to 
polyomaviruses to analyze the specificity of putative human anti-SV40 (Simian Virus 40) 
antibodies in case control studies assessing by serology the controversely discussed 
association of SV40 with human tumors. See the 2nd contribution.  
 
2.3 Analysis of humoral immune response in human sera using GST-L1 fusion proteins 
(vaccination study) 
 
The third contribution in this thesis aimed mainly to analyze in details the humoral immune 
response to HPV antigens induced by vaccination with HPV16 L1/E7 chimeric virus-like 
particles (cVLP) using sera from a clinical vaccination trial with 36 participants, 12 placebo, 
12 low-dose and 12 high-dose recipients (Kaufmann et al., 2007). Analyses were done by 
multiplex serology as briefly described above and by in vitro neutralization assays based on 
HPV pseudovirions carrying a SEAP reporter gene (Buck et al., 2005; Pastrana et al., 2004). 
 
As the participants were CIN II/III patients, it was not unexpected to detect a certain level of 
immune response at baseline (at week 0; W0). At this point, 21 and 6 participants had 
antibodies against HPV 16 L1 and E7, respectively, and 16 had HPV 16 neutralizing 
antibodies. None of the 12 placebo recipients showed any changes in the immune response; 
they did not seroconvert nor increase the reactivity (versus baseline) toward any of the 
antigens analysed. 
All 24 women who received the vaccine showed an HPV16 L1 immune response already two 
weeks (W2) after receiving the first vaccine dose. The increase in response was strong as 
very high MFI values at 1:100 dilution as well as high endpoint dilution titers were reached. 
The increase in high-dose (250 µg) vaccinees was higher than in low-dose (75 µg) vaccinees 
(134- and 45-folds respectively). The geometric mean titer (GMT) among the high-dose 
group was more or less stable until W14; whereas in the low-dose group a continuous low 
rate increase in GMT was observed until the level of the high dose-group was reached at 
W14. At W24 the titers decreased 2.5- to 3-fold in both groups. The immune status of 
patients before vaccination correlates with the degree of increase in the immune response 
upon vaccination. In baseline seropositive participants GMT at W2 was 30 fold higher than in 
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baseline seronegatives and still 3-fold higher at W14. There was a linear relationship of 
endpoint titer (titers range 100 to 8100) and MFI values at 1:100 (MFI range 155 to 9344)  
 
Vaccination leads also to generation of neutralizing antibodies. Eight of the vaccinees 
developed only a very weak neutralization response (border-line titers) over time, while 16 
showed strong responses. The increase in the neutralization titer was observed already at W2, 
1.8-fold stronger in the high-dose (GMT 1159) than in the low-dose group (GMT 661). At 
W14, the titer tripled among the high-dose and doubled in the low-dose recipients; but at 
W24 already decreased 5-fold and 3-fold, respectively, in both groups. Vaccinees baseline 
neutralization negative, at W2 reached a GMT of 283 only while the seropositives starting 
from 104 reached 487. The titers and the group difference did not change at W4 and W8, but 
with the increase at W14 the titer among baseline negatives became slightly higher than 
among the baseline positives, at W24 both fell to very similar low levels. No cross-
neutralizing antibodies to either HPV 18 or 11 were detected 
 
Cross-reactive antibodies to a variety of other HPV types than 16 including high- and low-
risk mucosal alpha types, and different cutaneous alpha, beta, gamma, mu and nu types have 
also been detected. Cross-reactivity signals were identified as either those already existed at 
baseline and upon vaccination increased or those only induced after vaccination (at least 3-
folds increase).  
All of the vaccinees seroconverted to at least one HPV type other than HPV 16 irrespective of 
vaccine dose. However, HPV 16 specific titers were 243- and 81-folds greater than cross-
reactive titers in high- and low-dose groups, respectively. The median time point of cross-
reactivity seroconversions in patients of the high-dose group was W2 versus W4 in the low-
dose group. At these weeks, the response plateau in most of the patients was reached. 
Frequency of cross-reactivity was generally higher in the high-dose than in the low-dose 
group with mean of 14 and 19 cross-reactive types in both groups, respectively. Cross-
reactivity was more frequent among the alpha mucosal types followed by the alpha cutaneous 
and least frequent among the skin HPV types. All participants developed cross-reactive 
antibodies to HPV 18 and 45 although these types belong to a different and phylogenetically 
distant species.  
 
All vaccinees (except one of the high-dose group) irrespective of the vaccine dose developed 
immune response to HPV16E7. The median time of serconversion in both vaccine groups 
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was W2. At this time point, the reactivity to HPV16 E7 in the high-dose group was 6.5-fold 
stronger than in low-dose recipients. The immune response in baseline seropositive 
participants was 3.4-fold higher than in baseline seronegatives. 
Vaccination induced also E7 cross-reactive antibodies to at least one other type than HPV 16 
in 13 vaccine recipients. However, the specific immune response to HPV16E7 was 2.5 
stronger than to any of the cross-reactive types. Additionally, the time of seroconversions 
were late (after W4) in comparison to the specific HPV 16 E7 antibody response (at W2). 
Cross-reactivity was more frequent in the high-dose than in the low-dose group and followed 
the phylogenetic classification. Most frequent cross-reactions were detected with the closely 
related HPV types of the α9 species. Cross-reactivity to types of α7 or α10 types was either 
absent or very rare in comparison to cross-reactivity observed for L1. 
 
Antibodies to at least one of the other HPV 16 early proteins (E1, E2, E4 and E6) in 7/12 
high-dose and 6/12 low-dose vaccinees were also detected. Responses were generally weak 
(MFI median 181, range 51-1217) and transient (some cross-reactions appeared only on a 
single time point and then diseappeared). Seroconversion to any of these early proteins (W8 
or later) occurred later than to HPV 16 E7 or L1 (W2). Antibodies to HPV16 E6 (36% of the 
vaccinees) were most frequent, followed by E4 (25%) and E2 and E1 (11% each). 
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3. General conclusions 
 
The experimental data presented in this PhD thesis shed light on GST fusion proteins and 
their suitability to replace the traditionally used VLP as antigens in HPV serology assays. It 
also analyzed in details, the immune response in human after natural infections versus 
response due to vaccination. This allowed for the following conclusions:  
 
From the mAb analysis study, we conclude the following 
1. The bacterial expression system in comparison to other expression systems (e.g 
baculovirus or insect cells) allows easier analysis of many HPV types belonging to different 
species. 
2. GST-L1 fusion proteins present most of the antigenic epitopes presented by VLP. They 
display the epitope repertoire of intact VLP (conformational) and also epitopes presented by 
denatured VLP (linear). 
3. GST-L1 fusion proteins display neutralizing, type-specific as well as cross-reactive 
epitopes. 
4. Cross-reactivity among HPV types can be inter-species, intra-species or mixed. It follows 
only loosely the phylogenetic grouping. Species-specific epitopes are either very rare or do 
not exist suggesting that the phylogenetic L1-based species definition may not define a 
serological unit. 
5. Distantly related mucosal and skin alpha HPV types share conformational epitopes. 
6. Cross-reactive epitopes are not necessarily cross-neutralizing.  
7. Neutralizing epitopes are always conformational and are mostly type-specific. Cross-
reactive epitopes are rarely neutralizing and if so they are rarely cross-neutralizing. 
8. Soluble L1 protein of one HPV type can specifically block cross-reactivity to a different 
HPV type.  
  
From the human vaccination study, we conclude the following: 
 
1. HPV16L1/E7 cVLP vaccine is highly immunogenic. 
2. CVLP can induce high titers of HPV 16L1-specific as well as high levels of E7-specific 
antibodies. 
3. High titers of neutralizing antibodies can also be induced upon vaccination with cVLP 
4. Luminex readout MFI values at 1:100 can be used as a surrogate to define or calculate the 
antibody and /or neutralizing titer of any serum. 
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5. The strength of the induced immune response depends on vaccine dose. 
6. The immune status before vaccination correlated with the strength of the induced immune 
response.  
7. CVLP vaccine induces wide L1 as well as E7 inter- and intra- species cross-reactivity 
patterns but not cross-neutralizing antibodies for distantly related types. 
8. Cross-reactivity follows loosely the phylogenetic classification and the higher the vaccine 
response the more cross-reactivity is induced. 
9. CVLP vaccine might have a probably immune reaction-induced cytopathic effect on cells 
and cause the release of other early proteins E6, E1, E2, and E4 present in the CIN cells.  
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Most anti-human papillomavirus (HPV) capsid antibody assays are based on virus-like particles
(VLP). We evaluated glutathione S-transferase (GST)–L1 fusion proteins as ELISA antigens for
determining type specificity and cross-reactivity of 92 VLP-specific monoclonal antibodies (mAb)
generated against nine mucosal alpha papillomavirus types of species 7, 9 and 10. The
antibody panel included 25 new mAb, and 24 previously published mAb are further characterized.
We determined the cross-reactivity patterns with 15 different HPV types representing 6 species
(alpha1, 2, 4, 7, 9 and 10) and neutralization and cross-neutralization properties with HPV
types 6, 11, 16, 18 and 45. Eighty-nine (97%) of the antibodies including 34, 71 and 14
recognizing neutralizing, conformational and linear epitopes, respectively, reacted with the
GST–L1 protein of the HPV type used as immunogen, with log titres ranging from 2.0 to 7.3. Of
these 89 antibodies, 52% were monotypic, 20% showed intra-species and 28% inter-species
cross-reactivity. Log neutralization titres to the immunogen HPV ranged from 1.7 to 5.6. A
single cross-neutralizing mAb (H6.L12) was found. ELISA titres were always higher than
neutralization titres. All neutralizing epitopes were conformational and mostly type-specific. Our
data show that bacterially expressed, affinity-purified GST–L1 fusion proteins display a broad
variety of epitopes and thus are well suited for detection of HPV antibodies. Cross-reactivity is
associated with linear as well as conformational epitopes. Distantly related mucosal and skin alpha
papillomaviruses share some conformational epitopes and the phylogenetic L1-based species
definition may not define a serological unit since no species-specific epitope was found.
INTRODUCTION
Human papillomaviruses (HPV) are small (about 55 nm in
diameter) non-enveloped DNA tumour viruses with a
tropism for squamous epithelia. The icosahedral protein
capsid is composed of 72 capsomeres (pentamers of the
major capsid protein L1) and contains a single molecule of
about 8 kbp closed circular double-stranded DNA.
So far, more than 100 HPV types have been fully
characterized by cloning and complete sequencing of their
genomes. Classification of HPV is based on the major
capsid protein L1 open reading frame nucleotide sequence:
HPV of the same genus show at least 60% sequence
identity, those of the same species at least 70%, those of the
same type at least 90% and those of the same subtype
(variants) at least 98% (de Villiers et al., 2004). HPV of the
genus alpha (15 species) mostly infect anogenital and oral
mucosa, some can additionally (species 2 and 8) or
exclusively (species 4) infect the skin. Many alpha HPV
can induce benign genital or common skin warts, while so
called high-risk types (most frequently HPV types 16 and
18) (Munoz et al., 2003) belonging to species 5, 6, 7, 9 and
11, can induce intraepithelial neoplasia, the precursor of
cervical cancer (Bosch & de Sanjose, 2003; Clifford et al.,
2003; de Villiers et al., 2004).
Upon infection with HPV, serum antibodies to L1 protein
can develop (Dillner, 1999; van Doornum et al., 1998;
Wang et al., 1996; Wideroff et al., 1999). This immune
response is highly type-specific (Carter et al., 1996, 2000;
Giroglou et al., 2001; Wang et al., 1997) and persists for
years (Carter et al., 2000; Dillner, 1999). L1 antibodies are
considered markers for current and past infection (Carter
et al., 1996; Carter & Galloway, 1997; Kirnbauer, 1996) and
are weakly associated with cervical cancer (Van Doornum
et al., 2003). In contrast, antibodies to the early
oncoproteins E6 and E7 that are consistently expressed in
HPV-transformed cells are strongly associated with cervical
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carcinoma (Lehtinen et al., 2003; Meschede et al., 1998;
Silins et al., 2002; Zumbach et al., 2000).
Analysis of HPV humoral immune responses faces some
limitations due to the large number of HPV types
associated with the different diseases and to difficulties in
producing sufficient quantities of infectious virus particles.
As an alternative to virion production, efforts were done to
reproduce the antigenic properties of virions by virus-like
particles (VLP). VLP are formed spontaneously after
overexpressing L1 by vaccinia virus (Hagensee et al.,
1993), plasmid vectors (Pastrana et al., 2004) or baculo-
virus (Kirnbauer et al., 1992) in yeast (Sasagawa et al.,
1995), mammalian, or insect cells (Le Cann et al., 1994),
respectively. VLP resemble papillomavirus virions in
morphology and display conformational and neutralizing
epitopes (Christensen et al., 1996a, b, 2001; Le Cann et al.,
1994). VLP-based ELISA (ELISA) is the standard technique
in HPV serology. It was developed to screen for antibodies
to HPV1 (Carter et al., 1993), HPV16 (Kirnbauer et al.,
1994), canine oral PV (CoPV) (Suzich et al., 1995),
cottontail rabbit PV (CRPV) and bovine PV 1 (BPV 1)
(Christensen et al., 1996a), BPV4 (Kirnbauer et al., 1996),
HPV45 (Touze et al., 1996), HPV6 and 11 (Touze et al.,
1998), HPV5 (Favre et al., 1998), HPV8 (Bouwes Bavinck
et al., 2000), HPV31, 33, 35, 18, 39 (Giroglou et al., 2001),
HPV59 (Combita et al., 2002) and HPV15, 20 and 24
(Feltkamp et al., 2003).
L1 of HPV11 and HPV16 expressed as fusion proteins with
glutathione S-transferase (GST) in E. coli spontaneously
form homogeneous capsomeres (Chen et al., 2000, 2001; Li
et al., 1997). Capsomeres generated from bacterially
expressed L1 of HPV11 and CoPV display neutralizing,
linear and conformational epitopes and induce neutralizing
antibodies upon experimental immunization (Rose et al.,
1998; Yuan et al., 2001).
Recently, GST–HPV L1 fusion protein-based antibody
detection systems have been developed for many HPV
types (Karagas et al., 2006; Sehr et al., 2002; Waterboer
et al., 2005).
Monoclonal antibodies (mAb) have been generated against
VLP of different HPV including types 6, 11, 16, 18, 31, 33,
35 and 45 (Christensen et al., 1996a, b; Combita et al.,
2002; Ludmerer et al., 2000). They are used to define HPV
capsid epitopes.
Epitopes on HPV capsids can be experimentally classified
as conformational (present on intact VLP and capsomeres)
or linear (displayed by synthetic peptides and denatured
L1) (Christensen et al., 1996a, b). Neutralizing epitopes
have also been identified in the L1 major capsid protein
(Christensen et al., 1994b; Giroglou et al., 2001; Rose et al.,
1998; White et al., 1998, 1999). To analyse HPV
neutralization properties, many systems have been estab-
lished using athymic mouse xenograft (Kreider et al.,
1987), raft culture systems (Meyers & Laimins, 1994) or
production of infectious HPV pseudovirions in vitro
(Roden et al., 1996; Touze & Coursaget, 1998; Unckell
et al., 1997). Pastrana and colleagues (Buck et al., 2005;
Pastrana et al., 2004) have developed an in vitro
neutralization assay utilizing HPV pseudovirions carrying
a secreted alkaline phosphatase (SEAP) reporter plasmid.
This study aimed, first, to evaluate GST–L1 fusion proteins
as ELISA antigens for detecting capsid-specific antibodies
against alpha papillomaviruses, and second, to use GST–L1
proteins of 15 different alpha HPV types to determine type
specificity and cross-reactivity of 92 mAb recognizing HPV
capsid epitopes. We show that GST–L1 fusion proteins
display almost all epitopes previously defined on VLP,
including conformational, linear and neutralizing epitopes.
Additionally, we describe a series of intra- and/or inter-
species cross-reactive epitopes and show that cross-
reactivity only loosely follows phylogenetic relationships.
We also show that neutralizing epitopes are always
conformational and mostly, but not always, type-specific.
METHODS
Cloning and expression of recombinant HPV L1 proteins. The
generation of GST–L1 fusion proteins from HPV6b, 16 and 18 (all
three lacking 10 aa at the N terminus) has been previously described
(Sehr et al., 2002). Similarly, the complete L1 open reading frames
(ORF) of HPV2, 3, 10, 11, 31, 32, 33, 35, 45, 52, 57 and 58 were
expressed as double fusion proteins with N-terminal GST and a C-
terminal undecapeptide (tag) of the SV40 large T-antigen. These
constructs and characterization of the fusion proteins will be
described in detail elsewhere (manuscript in preparation).
Transformation of the modified pGEX plasmids into E. coli strain
BL21 Rosetta DE3 (Invitrogen) and further expression and treatment
of the fusion proteins was performed as previously described (Sehr
et al., 2002).
Anti-HPV VLP monoclonal antibodies. Altogether, 89 tissue
culture supernatants and two ascites preparations of 91 mAb were
analysed (Tables 1, 2). Yet unpublished mAb were generated and
characterized as previously described (Christensen et al., 1990, 1994a,
b, 1996a, b; Muller et al., 1997; Sehr et al., 2002). Seventy-three mAb
were raised against VLP of nine different HPV types (HPV6, 16, 11,
18, 45, 31, 33, 52 and 35). Six mAb (the H263 series) were generated
against a hybrid containing residues 1–168 of HPV11 and residues
172–505 of HPV16. Another 12 mAb were generated against HPV11
VLP containing a G131S substitution (Tables 1, 2). All antibody
preparations used had an IgG concentration of at least 800 ng ml21
(Easy-Titer IgG kit; Pierce).
Detection of linear epitopes. Detection of epitope type was done
by an immunodot blot method. Bacterial lysates containing over-
expressed GST–L1 were diluted to 1 mg ml21 total lysate protein
either in PBS (native conformation) or in 0.2 M Na2CO3, pH 10,
1 mM DTT (denaturing conditions) and incubated at room
temperature for 30 min. For each mAb a nitrocellulose membrane
was prepared with two ml aliquots each of native and denatured
lysates. After drying, membranes were blocked (room temperature,
1 h) in 10% milk-PBS buffer, incubated (room temperature, 1 h)
with the mAb preparations diluted 1 : 50 in blocking buffer, washed
(6610 min) in PBS and incubated (room temperature, 1 h) with
peroxidase-conjugated goat anti-mouse antibody (Dianova). After
washing, antibody reactions were detected using Amersham ECL Plus
Western Blotting Detection System (GE Healthcare). The epitope type
%paper no. vir83145 charlesworth ref: vir83145&
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of four antibody preparations that reacted neither with native nor
with denatured GST–L1 could not be determined.
GST–L1 capture ELISA. Ninety-six-well PolySorp plates (Nunc)
were coated overnight at 4 uC with glutathione-casein and blocked
the next day as previously described (Sehr et al., 2001). The plates
were incubated (room temperature, 1 h) with the cleared GST–L1
fusion protein lysates diluted in casein blocking buffer to 0.25 mg ml21
total protein (saturating concentration) and washed. As a negative
control, GST-tag lysate was used in parallel. For titrations (each mAb
against the immunogen HPV L1), plates were incubated (room
temperature, 1 h) with threefold dilutions (starting concentration
1 : 10) of the mAb in casein blocking buffer (Sehr et al., 2001). For
cross-reactivity analyses, mAb were incubated (room temperature,
1 h) with the 15 GST–L1. Plates were washed, incubated (room
temperature, 1 h) with biotin-conjugated goat anti-mouse Ig,
incubated (room temperature, 30 min) with streptavidin–poly-HRP
(horseradish peroxidase), washed again and the colour reaction was
developed as previously described (Sehr et al., 2001). For 28 HPV16
mAb analysed at two separate days, the coefficient of determination of
the linear regression of the absorption values was R250.78.
HPV16 VLP-capture ELISA. HPV16 VLP-capture ELISA was
performed as previously described (Muller et al., 1997). Briefly,
plates (Nunc) were coated overnight at 4 uC with rabbit anti-HPV16
VLP polyclonal antibody diluted 1 : 200 in PBS and blocked the next
day with 5% milk, PBS, 0.05% Tween 20 (blocking buffer). As
antigen, HPV16 VLP (3.5 mg ml21 in blocking buffer) generated from
the same parental plasmid as GST 16L1 and purified by two gradient
centrifugations as previously described (Muller et al., 1997) were
used. Further assay procedures were as described above for GST–L1
capture ELISA.
Neutralization assay. In vitro neutralization assays based on HPV
pseudovirions carrying a SEAP reporter gene were done as previously
described (Buck et al., 2005; Pastrana et al., 2004). Briefly, 300 000
293TT cells ml21 (293 cells transfected with an expression plasmid
encoding a cDNA for SV40 large T-antigen) were seeded, infected
after 5 h with a mixture of serial mAb dilutions (starting
concentration 1 : 50) with the pseudovirions of the immunogen
HPV type and incubated (5 days, 37 uC). Cells supernatants were
assayed for SEAP using a chemiluminescent SEAP Reporter Gene
Assay (Roche Diagnostics). Pseudovirions of HPV16, 18, 45, 6 and 11
were available. For cross-neutralization analyses, all neutralizing mAb
were investigated at 1 : 50 dilution with the HPV pseudovirions of the
other types.
Data analysis and statistics. In all ELISA binding experiments,
lysate from bacteria expressing GST-tag alone was analysed in parallel
to define the reaction background. The measured absorbances (A) at
450 nm were expressed in milliunits (mAU). The net A450 value of a
mAb was obtained by subtracting the background reactivity from the
absorbance with the GST–L1-tag fusion protein. Monoclonal
antibodies were arbitrarily classified as reactive when the A450 value
at 1 : 90 dilution was equal to or greater than 110 mAU. The antibody
titre was defined as the last dilution yielding readings equal to or
greater than 110 mAU. For cross-reactivity experiments, a mAb
concentration close to saturation (mean 79% of Amax with the
immunogen HPV type; SD 15%) was used. All mAb were measured in
duplicate wells and the mean of the specific reactivity of the duplicate
values was taken as the final readout.
In SEAP neutralization assays, net relative light units (RLU) were
calculated by subtracting RLU of cells without mAb and pseudo-
virions (background) from RLU of cells treated with the mAb/
pseudovirion mixture. The end-point neutralization titre was defined
as the last dilution yielding ¢70% reduction in the SEAP activity in
comparison to the reactivity of the pseudovirions added without
antibody. For cross-neutralization, all mAb were analysed in duplicate
cultures.
RESULTS
Reactivity of VLP-specific mAb with GST–L1 of the
respective HPV type
Eighty-nine (97%) of the 92 mAb investigated reacted with
the GST–L1 fusion protein of the respective immunogen
HPV type (Tables 1, 2). The six mAb (H263.A2, H263.C3,
H263.F4, H263.G2, H263.H9 and H263.D1) generated
against a hybrid VLP containing residues 1–168 of HPV11
and residues 172–505 of HPV16 were analysed with both
HPV16 and HPV11 GST–L1. H263.A2 reacted only with
HPV16 while H263.G2 reacted only with HPV11 (Table 1).
The other four mAb reacted more strongly with HPV11
than with HPV16 (Table 2). All 12 mAb generated against
VLP of HPV11 L1 mutant G131S reacted with HPV11
GST–L1.
Of the 89 reactive mAb, 82 showed Amax values above
1500 mAU with log end-point dilution titres (the last
dilution giving a signal ¢110 mAU) varying from 3.3 to
6.3 for tissue culture supernatants and up to 7.3 for ascites
as antibody source (Tables 1, 2). The titration curves of
these mAb showed steep slopes, i.e. A450 values decreasing
from 80 to 20% of Amax within 10-fold dilution. For the
remaining seven mAb (H45.N5, H35.Q8, H35.H9, H35.N6,
H33.E12, H33.B6 and H18.A7), the Amax values were below
1100 mAU, log titres were between 2.0 and 4.3 and the
titration curves were flat, i.e. A450 values decreasing from
80 to 20% of Amax only within more than 100-fold
dilution. Fig. 1 shows six representative examples of mAb
titration curves.
Three mAb preparations, despite estimated IgG concentra-
tions of .800 ng ml21, were either very weakly reactive
(H6.C6 and H35.O3) or non-reactive (H16.L4) with the
respective GST–L1 protein (A450 ,110 mAU at 1 : 90
dilution) (Table 2) and were not analysed further. For
H6.C6 and H16.L4, the L1 N terminus is known to be an
essential part of the epitope (Christensen et al., 1996b), and
the HPV6 and 16 GST–L1 protein used here lacks the 10
N-terminal amino acid residues (Sehr et al., 2002). The
reason for the very weak reactivity of mAb H35.O3 remains
unclear. However, the reactivity of the other three mAb
generated against HPV35 VLP with HPV35 GST–L1 was
rather weak with low Amax and flat titration curves (Table 1,
Fig. 1).
HPV type specificity of mAb
HPV type specificity of the 89 reactive mAb was
investigated with GST–L1 fusion proteins of 15 HPV types
representing six alpha papillomavirus species (a1, a2, a4,
a7, a9 and a10). To allow cross-reactivity analysis in similar
conditions for all antibodies, we used a mAb concentration
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Table 1. Reactivity of mono-reactive HPV antibodies
Species Immunogen HPV
type
mAb Amax* (mAU) mAb titre (log10) Published data
ED Nd E/N§ Ig isotype Epitope
Type|| Essential aa Ref#
a9 16 H16.5A 2417 6.2 3.8 2.4 G2a C+ 266–297 339–365 A P
H16.14 J 2299 5.3 2.9 2.4 C 172–505 A
H16.3A 2283 3.8 3.5 0.3 C+ 172–505 A
H16.1A 2292 5.3 2.9 2.4 G2 C 266–297 339–365 A P
H16.6F 2276 6.2 3.5 2.7 G2a C+ 266–297 339–365 A P
H16.15G 2284 5.3 2 L 172–505 A
H16.U4 1976 6.8 G2a C+ 172–505 A B
H16.V5 1978 7.3 G2b C+ 266–297 339–365 A B
H16.E70 1645 3.8 2.3 1.5 G2b C+ 282 A B K
H16.4A 1942 5.8 3.5 2.3 C+ 172–505 A
H16.L4DD 164 1.0 G2a L N terminus A NC
H11 : 16** H263.A2 2332 5.8 2.9 2.9 C+ 266–297 339–365 A
31 H31.A6 2171 4.3 G1 C+ A B
33 H33.J3 2372 4.8 NC
H33.B6 1576 4.3 C NC
H33.E12 1355 4.3 C+ B
35 H35.H9 658 2.3 NC
H35.Q8 1166 3.8 C NC
H35.N6 340 2.9 NC
H35.O3DD 125 1.0 NC
52 H52.C1 2095 4.8 C NC
H52.B4 1854 4.3 C NC
H52.A7 2047 4.8 C NC
H52.D11 1980 4.8 C NC
a7 18 H18.K2 2531 6.2 2 M C B
H18.J4 2326 5.8 5.6 0.2 G2a C B
H18.R5 2371 4.8 2 G2b C B
H18.U15 2413 4.8 2 G1 C B
H18.G10 2384 5.3 4.1 1.2 G2b C B
45 H45.N5 429 3.8 2.9 0.9 C G
H45.L10 2102 4.8 3.8 1.0 C G
H45.C1 2188 5.3 3.2 2.1 M C B
a10 6 H6.M48 2105 3.8 2.9 0.9 G1 C+ 46 53 169–178 F I
H6.B10.5 1856 2.9 G2b C+ 46 53 169–178 B I
H6.N8 2347 4.3 2.3 2.0 G1 C+ 46 53 F I
H6.C6DD 288 1.5 G2a L- N terminus A NC
11 H11.H3 2145 5.8 4.7 1.1 G2b C+ 132 246 345–348 A D J
H11.F1 2178 5.3 4.4 0.9 G2a C+ 131 132 246 278 H J P
H11.B2 2249 6.2 4.7 1.5 G2b C+ 131 132 246 278 B J
H11.A3.2 2130 4.8 2.9 1.9 G2a C- 49–54 170–179 246 278 D I J
IV17B6(16) 1643 5.8 3.5 2.3 C MM
IV8D3(7) 1644 5.8 3.5 2.3 C MM
IV12D9(11) 1637 4.8 3.8 1.0 C MM
IV4A1(3) 1613 4.8 2.6 2.2 C MM
IV12D3(12) 1632 5.3 2.9 2.4 C MM
11G131Sdd G131S11.I1 2289 5.3 4.1 1.2 G1 C+ 262–289 D
G131S11.G3 2396 5.8 4.7 1.1 M C+ 262–289 345–348 D
G131S11.C2 2121 5.3 2.9 2.4 G1 C+ D
H11 : 16 H263.G2 1685 3.8 2.9 0.9 C 1–168 A
*A450 at 1 : 10 dilution in ELISA with GST–L1 of immunogen HPV type; mAU, absorbance milliunits.
DELISA titre.
dNeutralization titre.
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below but close to saturation for the immunogen HPV type
(Fig. 1).
Under these conditions, 46 (52%) of the mAb reacted only
with the GST–L1 fusion protein of the HPV type used for
immunization (Table 1), while the other 43 mAb (48%)
showed different levels of intra- and/or inter-species cross-
reactivity (Table 2).
Of the 43 cross-reactive mAb, 23 (54%) showed strong
(A450 relative to the type used for immunization .80%),
11 (26%) showed intermediate (relative A450 50–80%) and
9 (20%) showed weak (relative A450 ,50% but absolute
A450 .110 mAU) cross-reactivity with at least one other
HPV type. Of the 153 cross-reactions, 66 (43%) were
strong, 34 (22%) were intermediate and 53 (37%) were
weak. This suggests that the cross-reactive epitopes
recognized by about half of the cross-reactive antibodies
and in about half of all cross-reactions are very similar or
even identical to the specific epitope.
All mAb reactive with HPV31 (n51), HPV35 (n53) and
HPV52 (n54) were monotypic.
Of the 27 mAb generated against HPV16 VLP, 16 (59%)
were cross-reactive. Two mAb showed strictly intra-species
and four showed strictly inter-species cross-reactivity. The
other 10 mAb showed mixed intra/inter-species cross-
reactivity. Most frequent intra-species cross-reactions were
with HPV35 (n510), HPV31 and HPV58 (both n59),
followed by HPV33 (n57). HPV52 L1 (n54) showed the
least frequent cross-reactivity. On the other hand, the most
frequent inter-species cross-reactions were with HPV18
(n512), followed by HPV45 (n58), HPV11 (n57) and
HPV6 (n56). Cross-reactivity was less frequent with HPV2
and HPV32 (both n54), HPV10 (n53), and HPV57 and
HPV3 (both n52). Five HPV16 mAb cross-reacted also
with skin alpha papillomavirus types; in this group, cross-
reactivity was weak or absent with low-risk mucosal HPV
types 6, 11 and 32, but strong or intermediate with the
high-risk HPV types 18 and 45. Antibody H16.11B, which
recognized a conformational epitope, showed the broadest
cross-reactivity. It reacted with all 15 alpha papilloma-
viruses analysed, strongly with 12 HPV types and weakly
with types 6, 11 and 32.
From the four HPV33 mAb, only one cross-reacted
strongly with HPV52 and HPV58 and weakly with
HPV31, all from its own a9 species. In addition, a strong
but isolated cross-reaction was seen with the phylogeneti-
cally distantly related HPV32.
Of the 11 HPV18 mAb, 6 (55%) were cross-reactive. They
all showed mixed intra- and inter-species cross-reactivity
and reacted with the closely related HPV type 45. Five of
them reacted also with skin HPV types, i.e. HPV2 and
HPV57, and four also with HPV3 and HPV10. Fourteen
out of the 18 cross-reactions with skin types were strong
(n511) or intermediate. Antibody H18.A7, which reacted
only weakly with HPV18, showed very broad although
mostly weak (n57) or intermediate (n56) cross-reactions
with all other HPV tested. The other five mAb cross-
reacted with neither the mucosal high-risk HPV of the a9
nor the low-risk HPV of the a10 and a1 species, which is in
contrast to the frequent cross-reactions of HPV16 mAb
with HPV18.
Of the five HPV45 mAb, two showed strong and
intermediate intra-species cross-reactivity while inter-
species cross-reactivity was absent.
HPV6 and 11 are very closely related low-risk types of the
a10 species. Of the 34 mAb raised against these two types,
18 (53%) were cross-reactive, all recognized both HPV
types. Inter-species cross-reactivity was rare with only four
mAb additionally reacting weakly or intermediate with one
or two types of the high-risk HPV.
Direct comparison of mAb reactivity with HPV16
GST–L1 and VLP
In a direct experimental comparison, 32 mAb, encompass-
ing 28 raised against HPV16 and the 4 generated against
other HPV types but cross-reactive with HPV16 GST–L1,
were also analysed by HPV16 VLP ELISA. All HPV16-
specific mAb reacted in VLP-ELISA, including H16.L4,
which was non-reactive in GST–L1 ELISA; this mAb is
known to detect an epitope located within the N terminus
of L1 (Christensen et al., 1996a; Christensen, unpublished)
that is deleted in HPV16 GST–L1. GST–L1 and VLP titres
were similar (GST–L1 to VLP titre ratio: median 2.9, range
0.04–27) for the 14 neutralizing mAb, but GST–L1 titres
were much higher for the 13 non-neutralizing mAb (222,
3–6000). Also the 11 monospecific mAb had similar GST–
L1 and VLP titres (1, 0.05–10), whereas the GST–L1 titres
%paper no. vir83145 charlesworth ref: vir83145&
§Log10 of ratio of ELISA to neutralization titre.
||Reported epitope and neutralization type; C, conformational; L, linear; +, neutralizing; -, non neutralizing;
, epitope type is defined in this study.
#References: A, Christensen et al., 2001; B, Christensen et al., 1996a; D, Ludmerer et al., 2000; F, Christensen et al., 1996b; G, Combita et al., 2002;
H, Ludmerer et al., 1997; I, McClements et al., 2001; J, Ludmerer et al., 1996; K, Roden et al., 1997; MM, Martin Mu¨ller, unpublished; NC, Neil D.
Christensen, unpublished; P, Culp et al., 2007.
**H11 : 16, hybrid containing aa 1–168 of HPV11 and 172–505 of HPV16.
DDmAb not analysed further.
ddMutant HPV11 with G131S substitution.
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of the 16 cross-reactive mAb were always higher (50, 2.5–
6500). Finally, the GST–L1 to VLP titre ratios were higher
for the 9 mAb recognizing linear (27, 8–6000) than for
those 9 mAb recognizing conformational epitopes (3, 0.04–
800). In summary, GST–L1 display neutralizing, mono-
specific and conformational epitopes like VLP, but GST–L1
appears to display non-neutralizing, cross-reactive and
linear epitopes in larger quantity than highly purified,
antibody-captured VLP.
Neutralization activity of VLP-specific mAb
Seventy four mAb were analysed for neutralization of
HPV6, 11, 16, 18 and 45 (Tables 1, 2). Thirty four (46%)
mAb neutralized pseudovirions of the immunogen HPV
type. End-point neutralization log titres ranged from 1.7 to
5.6. Thirty three of the neutralizing mAb recognized a
conformational epitope and one (MM07) recognized a
linear epitope. Among mAb recognizing monospecific
epitopes, 28 out of 42 (67%) were neutralizing, in contrast
to only five out of 29 (17%) mAb recognizing cross-
reactive epitopes.
All neutralizing mAb were further investigated at a 1 : 50
dilution for cross-neutralization with pseudovirion pre-
parations of HPV6 and 11 (a10), 16 (a9), as well as 18 and
45 (a7). Cross-neutralization was observed only once; mAb
H6.L12 neutralized both HPV6 and the most closely related
HPV11 pseudovirions.
DISCUSSION
This study represents the largest and most comprehensive
analysis conducted so far on presence and type specificity
of epitopes displayed by HPV capsid proteins. It intro-
duced 25 new mAb and further characterized 24 previously
published mAb. It reproduced published data for 36 out of
42 mAb and the only differences observed were the
extremely weak binding reactivity of H35.O3 and H6.C6,
and the absence of binding (H16.L4) or neutralization
activity of mAb H16.J4 with HPV16, and G131S11.H5, -
.D2 and -.A10 with HPV11.
The majority of published HPV serology data has been
established using VLP-based ELISA assays. Here, we used
HPV L1 antibody assays based on bacterially expressed,
affinity-purified glutathione S-transferase L1 (GST–L1)
fusion proteins as antigens (Sehr et al., 2002). This assay
has been previously validated for HPV16 and 18 with human
and experimental mouse sera by comparison with VLP-
ELISA data (Davidson et al., 2003; Sehr et al., 2002). The
bacterial expression system allowed analysing 9 mucosal
HPV types that had been available before as VLP and 6 HPV
types, i.e. skin HPV2, 3, 10 and 57 as well as the mucosal
high-risk HPV type 58 and low-risk HPV type 32 that had
not been available before as VLP. These numbers reflect the
ease with which GST–L1 fusion proteins can be generated,
purified and applied in antibody assays.
The binding of 89 (97%) of the 92 mAb indicates that
GST–L1 fusion proteins (with the exception of HPV35)
present most (if not all) of the antigenic epitopes presented
by VLP. Only two mAb reacted extremely weakly and one
did not react with the GST–L1 protein of the respective
HPV type. H6.C6 and H16.L4 detect an epitope located on
the N terminus of L1 (Christensen et al., 1996a, b), and
GST–L1 preparations of HPV6 and 16 lack aa 1–10. Fusion
of GST to the L1 N terminus apparently did not inhibit
binding of any other mAb, indicating that all of them are
either targeting epitopes elsewhere or that GST fusion does
not affect N-terminal epitope conformation (Sehr et al.,
2002).
Four HPV35 specific mAb reacted very weakly, suggesting
that the HPV35 GST–L1 preparation lacked most of the
VLP-displayed epitopes for yet unknown reasons.
However, the presence of 3 conformational cross-reactive
epitopes (H16.8B, H16.11B and H263.C3) indicates at least
partially correct conformation of HPV35 GST–L1. H18.R5,
reported to recognize a conformational epitope on HPV18
and HPV45 VLP, reacted only with HPV18 GST–L1,
suggesting a subtle epitope difference of HPV45 GST L1.
Our results show that GST–L1 fusion proteins have the
epitope repertoire of intact VLP (conformational), but also
display epitopes presented by denatured VLP (linear).
Linear epitopes are also present on intact VLP preparations
either because they are surface-exposed on capsids or
because the VLP preparation also contains some denatured
L1, but reactions with intact VLP are usually weaker than
with denatured proteins (Christensen et al., 1996a). Our
direct comparison using twofold gradient-purified and
antibody-captured HPV16 L1 VLP as ELISA targets also
demonstrated the presence of all linear and all cross-
reactive epitopes in VLP ELISA, but in clearly lower density
than in GST–L1 ELISA.
%paper no. vir83145 charlesworth ref: vir83145&
Fig. 1. Representative dose–response curves for binding of HPV
VLP-specific mAb to GST–L1 fusion proteins. ELISA analysis of
serial dilutions of mAb preparations incubated with GST–L1 fusion
proteins immobilized via glutathione-casein to the ELISA plates.
Each mAb was analysed with the L1 protein of the immunogen
HPV type. Circles indicate the dilution used for cross-reactivity
analyses.
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Of the 89 mAb reacting with GST–L1, 71 are known to
recognize conformational epitopes, including 34 neutral-
izing epitopes, and 14 are known to recognize linear
epitopes, of which 8 were reported also to react with some
intact VLP preparations (see Tables 1 and 2 for mAb and
references). These findings suggest that the GST–L1 fusion
protein preparations display neutralizing and conforma-
tional as well as linear epitopes. Two mAb recognizing linear
epitopes (H16.B20, H16.S1) did not react with GST–L1 of
HPV33 or 31, respectively, in contrast to their reported
cross-reactivity with denatured VLP of these types, indic-
ating that the GST–L1 preparations of these types presented
these linear epitopes in insufficient amounts.
The titres of the different mAb preparations used in this
study varied by several orders of magnitude. Choosing of
the first dilution below saturation for cross-reactivity
experiments allowed comparing the strength of the cross-
reactivity signals and classifying them into three categories,
strong, intermediate or weak. In a previous, smaller
analysis of VLP cross-reactivity of some of the mAb used
here, only a uniform dilution of 1 : 50 of tissue culture
supernatants irrespective of the effective antibody concen-
tration had been applied (Christensen et al., 1996a).
Among the 89 reactive mAb, 46 reacted only with GST–L1
proteins of the specific HPV type used for immunization,
indicating that GST–L1 fusion proteins are displaying type-
specific epitopes. Although we analysed cross-reactivity
with 15 alpha papillomavirus types, as compared to a
maximum of 9 types in previous VLP studies, we cannot
exclude that some of the mAb classified here as monotypic
might turn out to be cross-reactive when analysed with
additional types. Previously published data suggested that
conformation-dependent mAb H16.11B and H16.8B might
be specific for HPV16 alone (Christensen et al., 2001), but
here we describe strong cross-reactivity to many other
mucosal and skin alpha papillomaviruses. In contrast, the
cross-reactivity to HPV11 GST–L1, which was not seen
with HPV11 VLP, was very weak. For mAb H16.7E we
confirm absence of cross-reactivity to HPV11 (Christensen
et al., 2001), but observed a weak cross-reactivity to
HPV35. However, we did not see any reactivity to the four
other HPV types in the same species (a9). For mAb H16.2F
we confirm the absence of cross-reactivity to HPV11
(Christensen et al., 2001), but we additionally found weak
cross-reactivity with HPV18 and HPV45 (both a7).
We describe new cross-reactivity for 12 additional
antibodies, including 5 raised against HPV16, one against
HPV18, two against HPV45, one against HPV33 and three
against the HPV11 G131S L1 mutant. Moreover, we extend
the cross-reactivity pattern for 12 mAb. Altogether we have
data for 43 cross-reactive monoclonal antibodies, encom-
passing a total of 153 individual cross-reactions. This
provides a comprehensive description of some features of
cross-reactive epitopes among human papillomaviruses.
Cross-reactivity follows only loosely the phylogenetic
grouping. Among very closely related HPV types, i.e.
HPV6b and 11 (.92% aa identity in L1) as well as 18 and
45 (88%), cross-reactivity is frequent (Table 3). Since no
other HPV types from species a10 and a7 were analysed, it
is unclear whether there might be more intra-species cross-
reactivity among these antibodies. Only two of the 17
cross-reactive mAb raised against a HPV type of the a9
species were strictly intra-species cross-reactive. These two
mAb both recognized only a subset of the six HPV types
analysed from this species, suggesting that species-specific
epitopes are rare or even do not exist. Furthermore, most
mAb with inter-species cross-reactivity did not react with
all members of the species of the HPV type against which
they were raised, indicating again that HPV species may
not share common epitopes.
%paper no. vir83145 charlesworth ref: vir83145&
Table 3. Summary of mAb reactivities
Immunogen*
HPV type
Reactivity Cross-Reactivity Pattern
All Mono- Cross- All Intra-species Inter-species Mixed
All 89 46 43 43 18 4 21
a9
16 27 11 16 16 2 4 10
31 1 1
33 4 3 1 1 1
35 3 3
52 4 4
a7
18 11 5 6 6 6
45 5 3 2 2 2
a10
6 8 3 5 5 4 1
11 26 13 13 13 10 3
*For grouping of mAb against hybrid H11 : 16 and mutant 11G131S see Tables 1 and 2.
Reactivity pattern of 92 mAb with 15 HPV types
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There were no mAb specific for all mucosal alpha
papillomaviruses analysed that also lacked reactivity to
any of the 4 alpha skin HPV. Many other cross-reactive
mAb did not recognize some of the most closely related
HPV, but rather showed cross-reactions with individual,
distantly related HPV of other species, including alpha skin
HPV described here for the first time. Two of the HPV16
mAb (H16.H5 and H16.9A) did not react with any of the 5
other HPV in species a9 but instead reacted selectively with
HPV18 L1. The weak cross-reaction suggests that the
epitope recognized on HPV18 is not identical to that on
HPV16. Antibody H16.H5 has been described to bind
HPV16 L1 peptide aa 174–185 (Christensen et al., 1996a).
HPV18 has 7 mismatches in the homologous sequence,
suggesting that weak cross-reactivity is not mediated by
this sequence. On the other hand, two other HPV16 mAb
(Ritti01 and MM07) reacted with 5 of the 6 a9 HPV types
and very selectively also with HPV45. One of them reacted
marginally even with skin HPV2 but not with closely
related skin HPV57. Monoclonal antibody H16.S1 cross-
reacted with mucosal HPV types including HPV35 (a9),
HPV18 and 45 (a7) and additionally with skin HPV types 3
and 10 (a2). It has been described to bind HPV16 L1
peptide aa 111–130, (Christensen et al., 1996a). Leucine
residues 122 and 126 appear to be critical since all non-
reactive HPV types have replaced at least one of them by an
aromatic residue and the weakly cross-reactive HPV10
differs at the neighbouring position (D127E).
While HPV18 was the type most frequently recognized by
cross-reactive HPV16 mAb (12 out of 16), only one (pan-
reactive H18.A7) of the 6 cross-reactive HPV18 mAb
recognized HPV16. Most frequently observed inter-species
cross-reactivity was directed against skin HPV3, 10 and/or
2, 57. Antibody H18.Q2 cross-reacted with HPV types 45, 2
and 57.
Of 14 mAb detecting a linear epitope, 13 were inter-species
cross-reactive and one (H16.15G) monotypic (Table 4). Of
71 mAb detecting conformational epitopes, 29 (41%) were
cross-reactive. While 16 of these recognized only closely
related HPV types (6/11 and 18/45), three showed weak
and four strong inter-species cross-reactions even includ-
ing skin HPV types. In conclusion, the cross-reactivity
observed here suggests that distantly related mucosal and
skin alpha HPV share conformational epitopes and that the
phylogenetic L1-based species definition may not define a
serological unit since no species-specific epitope was found.
For H16.J4, neutralizing activity was described by Combita
et al. (2002), whereas in our experiments this antibody
showed no HPV16 neutralization.
For five of the six cross-reactive neutralizing mAb, cross-
neutralization could be assessed. H6.L12 was strongly
cross-reactive with the very closely related HPV11 and
neutralized HPV11 with a similar titre as HPV6, which is in
agreement with previously published data (Christensen et
al., 1996b). Antibodies H16.2F, H6.F62 and Ritti01 and
MM07 were weakly cross-reactive with HPV18/45, HPV11,
and HPV45 (Ritti01 and MM07), respectively, but showed
no cross-neutralization with these types. The weak cross-
reaction indicates lower affinity of the mAb to the cross-
reactive epitope, which might be insufficient to induce
neutralization on the cross-reactive epitope, alternatively
the absence of cross-neutralization might indicate that the
cross-reactive epitope is functionally different, i.e. that
antibody binding does not lead to neutralization.
GST–L1 ELISA titres were always higher than neutraliza-
tion titres, as has been described previously (Combita et al.,
2002; White et al., 1999) (Tables 1, 2). ELISA log titres on
average were similar among monospecific (median 5.3,
range 3.8–6.2) and cross-reactive mAb (5.0, 2.0–6.2).
However, cross-reactive mAb rather consistently showed
lower neutralization log titres (2.5, 1.7–3.8) than the
monospecific mAb (3.5, 2.3–5.6). Thus, the ratio of ELISA
to neutralization titres was on average about 100-fold
higher among the cross-reactive (log median 3.3, range
2.4–3.6) than among the monospecific mAb (1.5, 0.2–2.9).
This may indicate that neutralization epitopes are highly
type-specific. The cross-reactive antibodies that are mono-
specific in neutralization might recognize the L1 surface
involved in neutralization (functional structure) only
partially because they also recognize neighbouring, non-
functional structures shared by other types, thus their
ability to induce a structural change or to block a surface
essential for the infection process is reduced, but could be
overcome in higher concentrations, resulting in lower
neutralization titres.
In conclusion, HPV capsid epitopes defining neutralizing
sites are always conformational and most of the mAb
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Table 4. Association of cross-reactivity of HPV mAb with linear and conformational epitopes
Epitope Reactivity Neutralizing
activity
All Monotypic Cross-reactive
Intra-species only Inter-species or mixed
Total 85 43 16 26 34
Conformational 71 42 16 13 33
Linear 14 1 0 13 1
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detecting monospecific conformational epitopes are neut-
ralizing. Monoclonal antibodies binding to conformational
cross-reactive epitopes are rarely neutralizing, and if
neutralizing they are rarely cross-neutralizing. Monospecific
mAb neutralize more efficiently than cross-reactive.
In summary, our data indicate that bacterially expressed
GST–L1 fusion proteins display the same epitopes as VLP
and therefore fulfil the essential requirements of antigens
for HPV serology. They are useful tools to define and to
recognize complex patterns of conformational and linear
cross-reactive epitopes. However, when extrapolating these
data to the analysis of human sera, it should be kept in
mind that the experimentally produced mAb analysed here
and human antibodies generated by natural HPV infection
may differ due to differences in kind of antigen
(recombinantly produced and purified VLP versus native
virions), host producing the antibodies (mouse versus
human), and site, dose and kinetics of immuniza-
tion (long-term and low dose in natural infection versus
short-term boosting with high doses in experimental
animals).
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The rhesus monkey virus Simian Virus 40 (SV40) is a member of
the polyomavirus family. It was introduced inadvertently to
human populations through contaminated polio vaccine during
the years 1956–1963, can induce experimental tumors in animals
and transform human cells in culture. SV40 DNA has been identi-
ﬁed in mesothelioma and other human tumors in some but not all
studies. We tested prediagnostic sera from 49 mesothelioma cases
and 147 matched controls for antibodies against the viral capsid
protein VP1 and the large T antigen of SV40 and of the closely
related human polyomaviruses BK and JC, and for SV40 DNA.
Cases and controls were identiﬁed among donors to the Janus
Serum Bank, which was linked to the Cancer Registry of Norway.
Antibodies were analyzed by recently developed multiplex serol-
ogy based on recombinantly expressed fusions of glutathione-S
transferase with viral proteins as antigens combined with ﬂuores-
cent bead technology. BKV and JCV speciﬁc antibodies cross-
reactive with SV40 were preabsorbed with the respective VP1 pro-
teins. Sera showing SV40 reactivity after preabsorption with BKV
and JCV VP1 were further analyzed in SV40 neutralization
assays. SV40 DNA was analyzed by SV40 speciﬁc polymerase
chain reactions. The odds ratio for being a case when tested posi-
tive for SV40 VP1 in the antibody capture assay was 1.5 (95% CI
0.6–3.7) and 2.0 (95% CI 0.6–7.0) when only strongly reactive sera
where counted as positive. Although some sera could neutralize
SV40, preabsorption with BKV and JCV VP1 showed for all such
sera that this neutralizing activity was due to cross-reacting anti-
bodies and did not represent truly SV40-speciﬁc antibodies. No vi-
ral DNA was found in the sera. No signiﬁcant association between
SV40 antibody response in prediagnostic sera and risk of mesothe-
lioma was seen.
' 2007 Wiley-Liss, Inc.
Key words: polio vaccination; viral infection; simian virus 40;
malignant mesothelioma
The rhesus monkey virus Simian Virus 40 (SV40), introduced
inadvertently to human populations through contaminated polio
vaccine during the years 1956–1963, has repeatedly been shown
to induce tumors in animal models and to transform human cells
in culture (reviewed in Refs. 1,2). Many types of tumors have
been observed, including mesothelioma, ependymoma, osteosar-
coma and non-Hodgkin lymphoma, apparently partly dependent
on the route of infection.2
The strong and consistent relation between experimental SV40
infection and cancer development in rodents has motivated the
investigation of its carcinogenic potential in humans. SV40 DNA
sequences have repeatedly been reported in cases of human can-
cers of essentially the same types as has been seen in rodents.3–7
In a meta-analysis including 528 mesothelioma cases and 468 con-
trols from 15 studies, the combined OR for the presence of SV40
DNA sequences in mesothelioma tumor tissue was 17 (95% CI
10–28).8 SV40 early region sequences have also been detected in
human peripheral blood cells, and in preparations of B and T lym-
phocytes from healthy subjects.9 Other studies of SV40 sequences
in tumor tissue have however seriously questioned these results,
suggesting positive ﬁndings to be caused by contamination or
other laboratory artifacts.10–12
Available epidemiological studies have mostly been based on
proxies of infection, such as being part of a population likely to
have been exposed to contaminated vaccine.13 The proportion of
actually vaccinated persons and the proportion of actually conta-
minated vaccines used are unknown factors. Descriptive studies
from the United States, Denmark, Sweden and Norway have not
shown higher cancer incidence among individuals likely to having
been exposed to contaminated vaccines.14–17 A limitation of these
studies is that the cohorts assumed unexposed to SV40 are born af-
ter 1963, and therefore in general too young to be at risk of most
cancer types. A case-control study from the United States where
individual vaccine status was ascertained did not support an asso-
ciation between SV40 and the development of brain tumor, meso-
thelioma or non-Hodgkin lymphoma.18
Knowledge of the extent and the natural course of SV40 infec-
tion among humans is still relatively scarce. In groups assumed to
have been exposed to contaminated vaccine 12–24% were sero-
positive for neutralizing antibodies, while in groups born after
vaccines were SV40-free seropositivity rates of 2–13% were
seen.19–21 Among laboratory workers handling monkeys or mon-
key kidney cells 40–55% have been found to be positive for SV40
neutralizing antibodies,20,22 and in zoo workers with direct contact
with nonhuman primates 25% had a positive response when an
enzyme immunoassay was used.23 Infection with human polyoma-
viruses BK (BKV) and JC (JCV), which are closely related to
SV40, is frequent and leads to strong antibody responses that can
cross-react with SV40 antigens.24 After performing competitive
inhibition experiments using BKV and JCV, the prevalence of
seropositivity in zoo workers was reduced to 10%.23 Results of
old and recent studies are thus difﬁcult to compare because of use
of different assay principles and varying sensitivities. Serological
studies published so far on antibodies to SV40 among cancer
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patients and their controls have indicated low prevalence of anti-
bodies to SV40,25 and a lack of association between cancer risk
and the presence of antibodies to viral proteins when measured
both at the time of diagnosis26,27 and prior to diagnosis.28
The interpretation of the repeated ﬁnding of SV40 in human
tumors is controversial. The question is whether SV40, if present,
is a causal factor in carcinogenesis, a cofactor acting only in con-
cert with other carcinogens (e.g. asbestos, in the case of mesothe-
lioma), an expression of the reactivation of a latent infection in an
immunocompromised host, or simply a result of laboratory con-
tamination.11 Under the assumption that SV40, like BKV and
JCV, infects and replicates in humans and persists in a latent
infection, an antibody response similar in type and extent to that
against BKV and JCV should be expected. Thus, SV40-speciﬁc
antibodies would be detectable in the phase before cancer devel-
opment. A difference in infectious activity of SV40 measured by
elevated antibodies in subjects that eventually developed mesothe-
lioma versus controls could indicate an association of SV40 and
human cancer. Viraemia, with identiﬁable viral DNA sequences in
serum, may be expected to be present during the acute infection,
but previous exposure may not necessarily be reﬂected by the
presence of SV40 DNA at a later point in time.
The aim of the present study was to investigate, for the ﬁrst
time, the risk of mesothelioma associated with the presence of
SV40 antibodies and SV40 genomic DNA in a study based on pre-
diagnostic serum samples from mesothelioma cases and controls.
In addition, the sera were investigated for the presence of antibod-
ies to the human polyomaviruses BK and JC. The 3 viruses have
about 70% genomic similarity with each other.29 The sera were
analyzed for antibodies to the major capsid protein VP1 (VP1) and
to the large T antigen (Tag), identiﬁed as the oncoprotein that
binds and inactivates p53 and pRb, cellular proteins with tumor
suppressor activity.30 To evaluate the SV40 VP1-reactive sera in
the presence and absence of SV40 cross-reactive BKV and JCV
speciﬁc antibodies all antibody measurements were performed
with and without preabsorption of the sera with an excess of solu-
ble VP1 proteins from BKV and JCV. Those sera that still reacted
positively with SV40 VP1 when preabsorbed with BKV and JCV
VP1 were further characterized in SV40 neutralization assays.
Material and methods
On the vaccination program in Norway
In Norway an estimated 3–5 million doses of potentially conta-
minated vaccine were used during 1956 through 1962. The total
population at the time was approximately 3.5 millions. Through
the whole period the Salk inactivated vaccine was used. The Sabin
live, attenuated oral preparation was not given until 1965, when
vaccines were free from contamination. The national vaccination
program varied somewhat during the period, but in general pre-
scribed 3 doses for children during their ﬁrst year and 1 dose at
age seven. In addition, vaccination was recommended for pregnant
women and persons aged 18 and below. Accordingly, 3 levels of
risk of SV40 infection through vaccination can be discerned; those
born 1921–1937 were possibly vaccinated, those born 1938–1948
were probably vaccinated, and those born 1949–1962 were almost
certainly vaccinated with potentially SV40-contaminated vaccine.
No speciﬁc information on the proportion of contaminated vaccine
or the level of contamination of the vaccines used in Norway was
available. A more detailed description of the Norwegian polio vac-
cination program has been published previously.17
Identiﬁcation of cases and selection of controls
The study base was deﬁned as the cohort comprised by the
Janus Serum Bank, established in 1972 and presently containing
more than 600,000 serum samples from over 300,000 healthy indi-
viduals. Samples have been collected in conjunction with repeated
regional health surveys and from blood donors. Samples are stored
at 225C. The serum bank has previously been used in other
studies of viral markers.31–33 The cohort was linked to the Cancer
Registry of Norway to identify all cases with a mesothelioma
diagnosis. Since 1953 all new cancer cases in Norway have been
recorded at the cancer registry based on the compulsory reporting
from all clinical and histopathological departments in the country.
The registry is considered to be virtually complete, especially for
solid tumors.
Between 1973 and 2003 altogether 1,251 new cases of mesothe-
lioma were reported to the Cancer Registry. Of these, 82 cases
(6.6%) had donated serum to the serum bank prior to their diagno-
sis, and were eligible for inclusion in the study. Basis for selection
was the classiﬁcation of the case as a malignant mesothelioma
(codes 9050/3–9053/3 according to the 2nd edition of the Interna-
tional Classiﬁcation of Oncology34). For 2 cases there was not
enough serum available for the analyses, and these cases had to be
excluded. To revise the histological diagnoses archival histopatho-
logical tissue samples were collected and examined with at least 4
immunohistochemical stainings35,36 and reviewed independently
by 3 pathologists in several steps. Eleven of the selected cases
were diagnosed as adenocarcinomas or other rare tumors of the
pleura or peritoneum, and in 20 cases no revision could be made
because of lack of representative material. This left 49 cases to be
included in the study.
For each mesothelioma case 3 controls free from cancer at the
time when the case was diagnosed, matched on age (61 year),
gender, period of blood sampling (66 months) and county, were
selected from the serum bank. A total of 147 controls were thus
included in the study.
Information on asbestos exposure
Asbestos exposure is the main risk factor for mesothelioma,37
the estimated etiological fraction for men in Norway being 84%.38
Information on occupation in 1960, 1970 and 1980 was available
from national censuses, coded according to The Nordic Classiﬁca-
tion of Occupations.39 All occupations in the 1970 census have
previously been classiﬁed as having high, moderate or little/no
asbestos exposure.40 The same classiﬁcation was here used for the
1960 and 1980 censuses. Indicators of ever vs. never exposure to
asbestos in the 3 censuses were combined to adjust for asbestos
exposure at 4 levels (never exposed, or highly or moderately
exposed at one, 2 or 3 censuses, respectively).
Serological analyses: Antibody capture assays
Serological analyses to measure antibodies to the chosen series
of viral proteins were conducted at the German Cancer Research
Center in Heidelberg, Germany. Frozen serum samples were
shipped on dry ice. They were analyzed for antibodies to VP1 and
to Tag of BKV and JCV and SV40. The antibody detection
method was based on glutathione-S-transferase (GST) capture
ELISA as described by Sehr et al.41,42 in combination with ﬂuo-
rescent bead technology as recently described.43
Brieﬂy, full-length viral proteins were expressed in bacteria in
fusion with an N-terminal GST domain. Glutathione cross-linked
to casein was coupled to ﬂuorescence-labeled polystyrene beads
(MultiAnalyte, Luminex, Austin, TX) and GST fusion proteins
were afﬁnity-puriﬁed on the beads directly in a one-step proce-
dure. Bead types of different color and each carrying a different
antigen were mixed and incubated with human sera at 1:100 dilu-
tion. Antibody bound to the beads via the viral antigens was
stained by biotinylated anti-human-Ig and streptavidin-R-phyco-
erythrin. Beads were examined in a Luminex 100 analyzer
(Luminex) that identiﬁes the bead color—and thus the antigen car-
ried by the bead—and quantiﬁes the antibody bound to viral anti-
gen via the median R-phycoerythrin ﬂuorescence intensity (MFI)
of at least 100 beads of the same internal color.
Background MFI (reactivity with GST alone, usually below 100
MFI) was subtracted from the MFI values obtained with speciﬁc
proteins to obtain net MFI. Negative values were set to 0. Cut-off
points of 175 and 650 MFI were used for all VP1 and T-antigen
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proteins, respectively. This was deﬁned arbitrarily before the code
of case-control status was broken based on visual inspection of the
cumulative histograms of the distributions of viral antibodies to
correspond with a common level where the MFI values started to
rise. Positive and negative standard sera were included in all anal-
yses. High sensitivity and speciﬁcity of SV40 VP1 and Tag anti-
body detection by these antigens was found in extensive analyses
using serum panels from SV40-infected and uninfected rhesus
monkeys and comparison with neutralization and immunoﬂuores-
cence assays (Sehr P, Viscidi R, Shah K, Pawlita M. Detection of
antibodies to VP1 and large T-antigen of polyomaviruses BK, JC
and SV40. Manuscript in preparation).
Speciﬁc blocking proteins in the serum dilution buffer were
used to evaluate the speciﬁcity of the SV40 VP1 antibodies. For
this purpose the VP1 proteins of the polyomaviruses and the L1
protein of Human papillomavirus type 16 were bacterially
expressed in full length as fusion proteins with an N-terminal
maltose binding protein (MBP). To analyze polyomavirus antibod-
ies without speciﬁc blocking, sera were preincubated with MBP-
HPV16 L1 lysate (2 mg/ml total lysate protein). To block BKV
and JCV antibodies that could cross-react with SV40 VP1, lysates
with MBP-VP1 proteins of BKV and JCV (1 mg/ml total lysate
protein each) were used simultaneously (BKV/JCV VP1 block).
For further speciﬁcity analysis lysate (1 mg/ml total lysate protein)
with MBP-VP1 of SV40 or of the B-lymphotropic polyomavirus
(LPV), another primate polyomavirus that may infect the human
population44 was added to the BKV/JCV VP1 block.
Serological analyses: SV40 neutralization assays
For neutralization assays immortal African green monkey kid-
ney cells (CV-1) were seeded on 48-well plates at a density of
6,000 cells per well and grown for 8 hr at 37C in a 5% CO2
atmosphere. Sera were diluted 1:50 in cell culture medium (Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% fetal
calf serum) and incubated with SV40 virions for 30 min on ice.
Cells were infected with the mixture and grown overnight, before
the cell culture medium was changed. After 48 hr of infection,
cells were harvested and seeded in duplicates on 15-well adhesion
slides (BioRad, M€unchen, Germany) at a density of 3,000 cells
per well. After 6 hr of incubation, the cells were ﬁxed overnight
with acetone/methanol (1:1) at 220C. On the next day, SV40 T-
antigen positive cells were stained with an experimental hamster
anti-SV40 tumor serum (1:250 dilution) and Cy2-labeled goat
anti-hamster Ig serum (Dianova, Hamburg, Germany; 1:500 dilu-
tion). Nuclei were counterstained with DAPI at 1 lg/ml. SV40
infection led to >50% immunoﬂuorescence positive cells within
48 hr of infection. As a positive neutralization control, an experi-
mental rabbit-anti-SV40 virion serum (1:500 dilution, SV40 VP1
titer >25,000) was used (<1% immunoﬂuorescence positive
cells). Means of duplicate values were computed, and samples
with <10% immunoﬂuorescence positive cells were considered
neutralization positive.
Sera showing SV40 neutralizing activity without preabsorption
were preabsorbed and reanalyzed. Serum preabsorption for neu-
tralization assays was carried out differently from serum preab-
sorption for antibody capture assays, because presence of crude
bacterial lysate was toxic for the cells. Sera were preabsorbed with
GST fusion proteins of either HPV16 L1 or BKV and JCV VP1 or
SV40 VP1 immobilized and puriﬁed on Glutathione-Sepharose.
Hundred microliter Glutathione-Sepharose (GE Healthcare) per
serum were incubated for 30 min at room temperature with freshly
prepared lysate from bacteria expressing GST fusion proteins of
HPV16 L1 and the Polyomavirus VP1 proteins. The sepharose
was pelleted (500 rpm, 5 min) and washed twice with cell culture
medium. Four microliter serum was mixed with 100 ll sepharose
beads and 100 ll medium (initial serum dilution 1:25) and incu-
bated for 30 min at room temperature. Afterwards, the sepharose
beads were pelleted again and 50 ll of the supernatant were mixed
with 50 ll medium (1:50 ﬁnal dilution). Then, the neutralization
assay was carried out as described earlier.
Detection of SV40 DNA in serum
Frozen serum samples were shipped on dry ice to the St. Olavs
Hospital, Norway, and analyses were conducted at the Department
of Pathology and Medical Genetics. Proteinase K (QIAGEN, Hil-
den, Germany) was used for protein digestion and DNA-extraction
by Gene Vision BioRobot M48 (QIAGEN), using the standard
protocol of MagAttract1 DNA M48 kit (QIAGEN, West Sussex,
UK). Fifty microliter DNA eluate was obtained from each sample.
Primers were designed to amplify 239 bp of the SV40 enhancer
region containing the double 72 bp repeat (SV40en1F: 50-aac tgg
gcg gag tta ggg, SV40en2R: 50-tac ctt ctg agg cgg aaa ga) and 257
bp of the C-terminus of the large T-antigen (SV40Tcend2F: 50-ggg
agg tgt ggg agg ttt t, SV40Tcend2R: 50-atg tgg cta tgg gaa ttg ga).
PCR reactions were performed in 25 ll reaction volume with
5 ll DNA eluate containing 50–100 ng total DNA and Gold
Buffer (Applied Biosystems, Foster City, CA), dNTP, primer,
AmpliTaqGold1DNA Polymerase (Applied Biosystems) and
MgCl2 following the standard protocol. After denaturation (95C,
7.5 min) DNA was ampliﬁed in 40 cycles (95C, 30 sec; 56C,
30 sec; 72C, 30 sec) followed by ﬁnal elongation (72C, 7 min).
The size of PCR-products was determined by electrophoresis in
4% agarose minigels (E-gel, Invitrogen, Carlsbad, CA.). Twenty
base pair DNA ladder (Sigma-Aldrich, St. Louis, MO) was used
as size marker. Positive control DNA from a human osteoblast
cell line transfected with SV40 large T-antigen (hFOB 1.19,
ATCC number CRL-11372) and water as negative control were
included in all PCR assays. Analytical sensitivity with hFOB 1.19
DNA was 5 pg for the SV40 enhancer and 0.5 pg for the SV40
Tag C-terminus, corresponding to DNA of 1 and 0.1 cell, respec-
tively, necessary for SV40 sequence detection. PCR-products
were cut out of the gel and extracted according to the MinElute
Gel Extraction Kit Protocol (QIAGEN, Hilden, Germany). DNA
sequencing was performed with the CEQ 8,000 sequencing system
(Beckmann Coulter, Fullerton, CA).
Statistical methods
Antibody levels were measured on a continuous scale and used
as dichotomous variables in the statistical analyses. Box-plots
were produced to visualize the distribution of antibody levels for
cases and controls separately, and t-tests were run for formal com-
parison of the distributions. To evaluate cross-reactivity between
the virus markers, Spearman’s correlation coefﬁcients between the
6 antibodies to the 3 polyomaviruses included were calculated. To
estimate the risk of mesothelioma conditional logistic regression
was used to calculate the odds ratios (ORs) for being a case given
a positive response to one of the selected viral antibodies. Ninety-
ﬁve percent conﬁdence intervals (95% CIs) were computed.
Adjustment for age, gender, time of blood sampling and county
was included in the matched design of the study. All ORs were
additionally adjusted for asbestos exposure at 4 levels. The soft-
ware program Stata45 was used in all statistical analyses.
Approval from the ethical committee for medical research in
Norway and permission from the Norwegian Data Inspectorate to
perform the study was obtained.
Results
Of the 49 mesothelioma cases included, 41 men and 8 women,
38 were pleural, 1 mediastinal, 1 pericardial, 7 peritoneal, 1 both
pleural and peritoneal and 1 was located in the scrotum. Forty-one
were epithelial, 1 sarcomatous and 7 mixed type. Year of birth
ranged from 1923 to 1951 (mean 1938, interquartile range 1929–
1947), blood samples were drawn between 1972 and 1991 (mean
1981) and cases were diagnosed between 1980 and 2002 (mean
1996, interquartile range 1992–1999). Age at diagnosis ranged
from 40 to 79 (mean 57, interquartile range 51–67). The time span
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between serum sampling and cancer diagnosis ranged from 0.4–
30 years, with a mean duration of 15 years (interquartile range
8–22 years). Only one case had less than 1 year between blood
sampling and diagnosis.
Six (12.2%) of the cases and 17 (11.6%) of the controls were
born 1949–1951 when vaccination with possibly contaminated
vaccine was considered almost certain. Additionally, 20 (40.8%)
cases and 61 (41.5%) controls were considered probably exposed
(born 1938–1948). Among cases and controls, 8.2% and 2.0%,
respectively, reported jobs entailing high or moderate exposure to
asbestos at all 3 censuses. The prevalence of exposure to asbestos
at any census was 26.5% among cases and 21.1% among controls.
Mesothelioma risk for asbestos exposure was increased with an
OR of 4.5 (95% CI 1.0–20.9) for those exposed at all 3 censuses
compared to those never exposed.
Prevalence and level of VP1 antibody reactivity in the 196 sera
analyzed was very high for BKV (94%, median reactivity of the
positive sera 3,059 MFI) and JCV (77%, 4,029 MFI) (Figs. 1a and
1b). The majority (58%) of the sera also reacted with SV40 VP1,
but levels of antibody reactivity were much lower (median reactiv-
ity of the positive sera 895 MFI).
Blocking of BKV and JCV VP1 antibodies by serum preincuba-
tion with soluble MBP-VP1 fusion proteins of these 2 viruses
drastically reduced BKV and JCV VP1 antibody levels (Figs. 1a
and 1b). In the 196 sera analyzed the BKV/JCV VP1 block efﬁ-
ciently suppressed BKV VP1 antibodies, 99% of the 185 positive
reactions were blocked by at least 95%, and 98% of the positive
reactions were blocked below cut-off. For JCV VP1 antibodies the
block was slightly less efﬁcient, 90% of the 150 positive reactions
were blocked by at least 95%, and 85% of the positive reactions
were blocked below cut-off. The BKV/JCV VP1 block also drasti-
cally reduced antibody reactions with SV40 VP1, but to a lesser
extent than with BKV and JCV VP1 (Figs. 1a and 1b). Of the 114
initially SV40 VP1-reactive sera only 81% could be blocked by
95%, 23 of the sera (20% of initially positive sera, 12% of all
sera) remained above cut-off. Some of the remaining SV40 VP1
reactions were still rather strong: 10 out of 23 (43%) were above
33 cut-off, versus only 1 out of 3 (33%) and 1 out of 30 (3%) for
BKV and JCV, respectively. These results indicate that the majority
but not all of the SV40 VP1 antibody reactions in these human sera
are due to BKV and JCV antibodies cross-reacting with SV40 VP1.
In the absence of the BKV/JCV VP1 block the SV40 VP1 anti-
body reactivities were slightly correlated with BKV VP1 and JCV
VP1 antibodies, the Spearman’s correlation coefﬁcient rho being
0.29 and 0.16, respectively (Table I). The SV40 VP1 antibody
reactivity remaining after the BKV/JCV VP1 block was unrelated
to BKV and JCV VP1 antibodies as shown by very low rho values
of 20.06 and 20.03 between the blocked SV40 VP1 antibodies
and unblocked BKV and JCV VP1 antibodies, respectively, and
was also unrelated to the blocked BKV and JCV VP1 antibodies
(rho 0.08 and 20.05, respectively, not shown). The correlation
between the blocked and the unblocked SV40 VP1 antibodies
remained with a rho value of 0.46 (not shown).
Addition of soluble SV40 VP1-MBP fusion protein to the BKV/
JCV VP1 block solution abolished the remaining SV40 VP1 anti-
body reactivities for all sera except one, whereas addition of VP1-
MBP fusion protein of the B-LPV, another primate polyomavirus
distantly related to SV40, BKV and JCV, did not.
All 23 ‘‘nonblockable’’ sera that still reacted above cut-off with
SV40 VP1 when preincubated with BKV/JCV VP1 were analyzed
for SV40 neutralizing activity, together with 8 ‘‘blockable’’ sera
that reacted with SV40 VP1 when preincubated with HPV16 L1
(median 1,450 MFI, range 1,109–4,939 MFI), but not anymore (0
MFI) when preincubated with BKV/JCV VP1, and 8 ‘‘non-
reactive’’ sera that did not react with SV40 VP1 (0 MFI) when
FIGURE 1 – Distributions of antibody reactivities against SV40,
BKV and JCV VP1 (a), bottom enlarged in (b) and Tag in mesothe-
lioma cases (n 5 49) and controls (n 5 147) with (1) and without
(2) preabsorption of antibodies to BKV and JCV VP1 (c). Boxes
encompass 25 and 75 percentiles with medians indicated by horizontal
bars, whiskers indicate 10 and 90 percentiles. Filled (cases) and empty
(controls) circles indicate individual outliers, cut-offs used to distin-
guish antibody-positive and -negative values are shown as dashed hor-
izontal lines (175 and 650 MFI for VP1 and Tag, respectively).
TABLE I – SPEARMAN’S CORRELATION COEFFICIENTS FOR THE ESTIMATES OF ANTIBODIES TO THE POLYOMAVIRUSES (p-VALUES)
SV40 VP1 unblocked SV40 VP1 blocked BKV VP1 unblocked JCV VP1 unblocked SV40 Tag unblocked BKV Tag unblocked
BKV VP1 unblocked 0.29 (0.00) 20.06 (0.41)
JCV VP1 unblocked 0.16 (0.00) 20.03 (0.71) 0.02 (0.77)
SV40 Tag unblocked 0.38 (0.00) 0.07 (0.31) 0.38 (0.00) 0.08 (0.29)
BKV Tag unblocked 0.15 (0.00) 20.4 (0.61) 0.27 (0.00) 0.09 (0.22) 0.67 (0.00)
JCV Tag unblocked 0.23 (0.00) 20.00 (0.95) 0.32 (0.00) 0.11 (0.11) 0.68 (0.00) 0.78 (0.00)
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preincubated with HPV16 L1. Five neutralizing sera were identi-
ﬁed, all of which belonged to the group of the ‘‘nonblockable’’
sera. Four of these were positive in 2 out of 2 assays, 1 serum (no.
143) was tested only once (1/1). The 5 neutralizing sera were pre-
absorbed with HPV16 L1, BKV/JCV VP1 or SV40 VP1, and then
analyzed again for SV40 neutralization. Four of the 5 sera showed
neutralizing activity also when preincubated with HPV16 L1, 1 se-
rum (no. 143) failed to reproduce the neutralization activity
observed in the screening assay. All 5 sera did not exhibit neutral-
izing activity anymore when preabsorbed with either BKV/JCV
VP1 or SV40 VP1, respectively.
Antibody reactivities to Tag of the 3 polyomaviruses were
much less prevalent (15% for SV40, 19% for BKV and 19% for
JCV) than to the VP1 proteins (Fig. 1c). The BKV/JCV VP1 block
had no signiﬁcant effect on Tag antibodies. SV40 Tag antibodies
were correlated with those against BKV and JCV Tag (rho 0.67
and 0.68, Table I) indicating a substantial cross-reactivity.
The distributions of antibody responses in cases and controls
are shown as box-plots in Figure 1 and results of the multivariate
analyses of mesothelioma risk for the presence of positive antigen
response in Table II. Only results adjusted for asbestos exposure
are given, although this adjustment did not change the overall
results essentially. No signiﬁcant associations with any viral anti-
body response were seen. All but one of the effect estimates were
above unity, the highest OR being associated with high (> 3* cut-
off) level of SV40 antibody response in the presence of BKV/JCV
VP1 block. When the subgroup of cases and controls probably or
certainly vaccinated with contaminated vaccine was analyzed,
there was also no signiﬁcant association with antibodies against
the SV40 antigens although the OR associated with high titers
against SV40 VP1 was 3.2 (95% CI 0.8–13.0).
Most of the serum samples gave no SV40 PCR products; only
few resulted in a PCR product (25 of the enhancer and 7 of the C-
terminus) detectable by electrophoresis and ethidium-bromide
staining. DNA sequencing of these products showed no SV40 or
SV40-related sequences, therefore the products were classiﬁed as
unspeciﬁc.
Discussion
This is the ﬁrst study to investigate the association of prediag-
nostic SV40 markers to subsequent risk of mesothelioma, and to
apply a panel of serological assays on the same serum samples.
The cases and controls were selected from a well-deﬁned study
base, the Janus Serum Bank. The ascertainment of cancer diagno-
ses was based on the Cancer Registry of Norway, considered to be
virtually complete on solid tumors. All cases were histologically
veriﬁed at the time of diagnosis, and an additional extensive im-
munohistochemical investigation was performed in conjunction
with the present analysis. Selection of controls from the same
study base that have yielded the cases ensured an unbiased com-
parison group. A major limitation of the study is the small sample
size. However, the number of cases is the total of veriﬁed meso-
thelioma cases with available prediagnostic serum that have arisen
in Norway since 1972. Additional analyses were also done includ-
ing the 20 cases lacking other veriﬁcation than initial histology at
the time of diagnosis, and their corresponding controls. These
analyses did not give any materially different results.
Only 26% of cases were classiﬁed as asbestos exposed, which is
much lower than what would be expected in light of the attribut-
able fraction of 84% estimated previously.38 This may be
explained by the relatively crude asbestos exposure estimate based
on census information from 1 to 3 points in time. However, the
risk estimate of 4.5, associated with the highest exposure level,
was approximately as expected and comparable to what has been
seen in other studies.
One major question in SV40 epidemiology is the validity of the
antibody measurements. Recently published studies have shown
that SV40 reactivity in human sera may be almost entirely a result
of cross-reactivity with BKV and JCV antibodies.24,25,46 Also in
the present study, when SV40 VP1 antibodies were measured in
the antibody capture assay without precautions to suppress cross-
reactive BKV and JCV VP1 antibodies they were correlated with
BKV and/or JCV VP1 responses.
To eliminate BKV and JCV VP1 antibodies that might cross-
react with SV40 we developed a potent blocking assay based on
soluble BKV and JCV VP1 proteins over-expressed in bacteria in
fusion with MBP. The efﬁciency of the combined BKV/JCV VP1
block was demonstrated here by the strong, almost complete inhi-
bition of all BKV VP1 responses and most of the JCV VP1
responses. As expected for cross-reactive antibodies also SV40
VP1 reactivities were strongly suppressed by the BKV/JCV VP1
block, however the SV40 reactivity of a substantial fraction of
sera (12% of all sera and 20% of initially positive sera) could not
be completely inhibited. Also, 10 (43%) out of the 23 SV40 VP1
reactivities remaining in the presence of the block were strong
(>3* cut-off) versus only 1 out of 3 (33%) and 1 out of 30 (3%)
for BKV and JCV, respectively. These remaining SV40 VP1 anti-
body reactions could represent true SV40 infections in humans or
could still be cross-reactive antibodies resulting from infection
with another, yet unidentiﬁed human polyomavirus. During devel-
opment of the BKV/JCV VP1 block we observed that use of VP1
of only 1 of the human polyomaviruses in the blocking buffer was
rather inefﬁcient in blocking SV40 VP1 reactivities (Waterboer T,
Rizk R, Pawlita M, unpublished observation) indicating that dif-
ferent human polyomaviruses can induce cross-reactive antibodies
to different epitopes on SV40 VP1.
The prevalence of SV40 VP1 antibody reactivities in the anti-
body capture assay under BKV/JCV VP1 block conditions was
10.9% among controls, but was reduced to 4.1% when the higher
cut-off point was chosen. These prevalences are higher than would
be expected compared to previous studies, which however used
TABLE II – PROPORTION OF CASES AND CONTROLS WITH POSITIVE ANTIBODY RESPONSE AND ODDS RATIOS (OR) OF MESOTHELIOMA FOR THE
PRESENCE OF ANTIBODIES TO SELECTED VIRAL PROTEINS WITH CORRESPONDING 95% CONFIDENCE INTERVALS (95% CI)
Virus marker
Positive antibody
response (n)
Positive antibody
response (%)
Whole sample (49
cases/147 controls)
Born 1938–195126
(cases/78 controls)1
Cases Controls OR 95% CI OR 95% CI
SV40 VP1 unblocked 114 65.3 55.8 1.5 0.8–2.9 1.0 0.4–2.2
SV40 VP1 blocked 23 14.3 10.9 1.5 0.6–3.7 1.4 0.4–4.7
SV40 VP1 blocked and high titer2 10 8.2 4.1 2.0 0.6–7.0 3.2 0.8–13.0
SV40 VP1 unblocked and neutralized3 5 2.0 2.7 0.8 0.1–6.7 1.0 0.1–9.6
SV40 VP1 blocked and neutralized3 0 0 0 – – – –
BKV VP1 95.9 93.9 1.7 0.3–8.4 1.7 0.2–14.5
JCV VP1 81.6 74.8 1.5 0.6–3.7 2.1 0.6–7.4
SV40 Tag 18.4 14.3 1.4 0.6–3.2 0.7 0.2–2.5
BKV Tag 22.5 18.4 1.4 0.6–3.0 0.9 0.3–2.6
JCV Tag 18.4 19.1 1.0 0.4–2.2 0.3 0.1–1.4
1Certainly or probably vaccinated, according to vaccination program.–2MFI > 3* cut-off.–3All previously positive and a selection of negative
samples retested, total sample included in statistical analysis.
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different assays and different cut-off deﬁnitions. Knowles et al.,
using a micro well SV40 neutralization assay without BKV or
JCV block, described an SV40 seroprevalence in human sera of
3.2%.46 Carter et al., using a VLP-based ELISA found 6.6% SV40
seroprevalence, but none of the positive reactions remained after
competition with BKV or JCV VLP.25 In accordance with this, in
the present study only 5 positive samples remained when all previ-
ously positive samples and a selection of negative samples were
retested in a neutralization assay, and none of these could neutral-
ize SV40 when BKV/JCV was blocked.
Even if the SV40 VP1 antibody response measured while block-
ing the activity of BKV and JCV VP1 antibodies were taken to
represent true SV40 infection, no large differences between cases
and controls are seen in the overall analyses, indicating no associ-
ation between SV40 infection and subsequent mesothelioma risk.
The results from the additional neutralization assays strongly sup-
port this conclusion. This may imply that the frequent ﬁnding of
SV40 DNA fragments in mesothelioma tumors either is caused by
enhanced viral replication favored by the disease process,47 or that
it simply stems from contamination.10,11
The study was designed on the assumption that SV40 in humans
induces persistent infections with a continuous and relatively high
production of antibodies as it does in monkeys24 and similar to the
serum responses seen with BKV and JCV infections in humans.
Antibodies to VP1 are then expected to be a marker of acute or
persistent infection. However, this may not be the case for SV40.
Relatively little is known about SV40 infections in human popula-
tions. Early serological studies have indicated that individuals
who received SV40-contaminated vaccines may develop moderate
to high titers of SV40 neutralizing antibodies.19,48 But these titres
may not persist over decades. In the present study all serum sam-
ples were collected at least 10–15 years after potential exposure.
Several studies of recently collected sera from age groups prob-
ably vaccinated with SV40-contaminated preparations also have
not found high-titre SV40.21,25,46,49–51 It should be noted, how-
ever, that all comparisons with previous serological results might
be dubious because of the difﬁculties encountered with cross-reac-
tivity of antibodies.
It is also possible that antibodies to Tag are produced only dur-
ing the acute infection and then later as the carcinogenic process
is active. Thus, if there were an association with cancer risk, Tag
may not be expressed in sufﬁcient amounts for the detection of a
measurable antibody response before a tumor mass of a reasonable
size had developed. This means that the absence of an association
of SV40 Tag antibodies as seen here in prediagnostic sera of mes-
othelioma patients cannot rule out a potential association of SV40
with mesothelioma. The SV40 speciﬁcity of the Tag antibody
reactivities presented here is limited since these antibodies are
highly correlated with BKV and JCV Tag antibodies and in con-
trast to the VP1 antibody analyses so far no blocking system has
been developed to suppress the presumed SV40 Tag cross-reaction
of BKV and JCV Tag antibodies.
Even if no true SV40 antibody response was seen, it may be of
interest to note that the ORs for all serological markers, i.e. also
BKV and JCV tend to be elevated above unity, even if nonsigniﬁ-
cantly so. In most studies, only single antigens are being studied.
Here, a series of related viral proteins have been investigated. It
would be of interest to test larger mesothelioma samples and also
other cancer types, to investigate whether this higher seroreactiv-
ity is a consistent feature of mesothelioma carcinogenesis or even
a more general phenomenon related to cancer development.
The analyses of SV40 DNA sequences in serum yielded no pos-
itive results. Positive and negative controls were always included
and yielded the expected positive and negative PCR results. Any
presence of viral fragments many years after an infection in cases
and not in controls would have strongly supported the hypothesis
of a role of SV40 in carcinogenesis. The absence of these markers,
though, cannot be taken as strong evidence for the opposite, since
viral fragments tend to be cleared from the circulation after the
acute infection. In a recent study on BKV and neuroblastoma no
BKV-DNA was detected in serum in spite of a seroprevalence of
83% in cases and 80% in controls.52
Conclusion
In the present study, a panel of serological assays was applied
on preclinical serum from mesothelioma cases and controls to
identify a possible association with SV40 infection. With increas-
ing speciﬁcity of the assays used, the prevalence of SV40 positiv-
ity decreased, so that no truly SV40-antibody positive samples
were identiﬁed among cases and controls. No signiﬁcant associa-
tion between SV40 antibody response in prediagnostic sera and
risk of mesothelioma was seen. Nonsigniﬁcant, higher reactivities
were observed among the cases for all 3 polyomaviruses, indicat-
ing a possible prediagnostic difference between cases and controls
that may warrant further investigation.
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Abstract 
 
High-risk human papillomavirus types are the main etiologic agent of cervical cancer and its 
precursor lesions. Many clinical and preclinical prophylactic vaccine trials were conducted 
using virus-like particles (VLP) which resemble the native virions physically and 
immunologically. Chimeric VLP (cVLP) consisting of C-terminally truncated L1 protein 
fused to sequences of the HPV16 E7 oncoprotein have been recently used in a combined 
protective and therapeutic vaccine trial (Kaufmann et al 2007). CVLP vaccine showed a good 
safety profile and could induced HPV 16 L1 as well as E7 antibodies. In this study, we aimed 
to analyze this humoral immune response in detail. 
The vaccination target group was women diagnosed with cervical intraepithelial neoplasia 
(CIN) grade II or III. The vaccine was given either in a low- (75 µg) or a high-dose at weeks 
0, 2, 6, and 12. Blood samples for serology were collected at weeks 0, 2, 4, 8, 14, and 24. and 
assayed for induced antibodies using multiplex serology and pseudovirion-based 
neutralization assay. 
Of the study participants, 58% and 17% had naturally induced HPV16 L1and E7 antibodies at 
study entry, respectively. 44% had neutralizing antibodies. None of the placebo recipients 
showed any changes in the immune response over time. Upon vaccination, HPV 16 L1 
antibodies were induced in all patients, with titers up to 200,000 in both vaccine groups. L1 
neutralization titers ranged from 60 to 5400 in the low-dose and up to 48,600 in the high-dose 
group. Response to E7 was generally weaker. Cross-reactivity to L1 as well as to E7 was very 
frequent with the closely related HPV 31, 35 and 33 types, however, less frequent cross-
reactivity to L1 of alpha cutaneous and skin types was observed. No cross-neutralization to 
HPV18 or 11 was induced. Antibodies against 16E6, E4, E2 and E1 were also induced.  
In summary, HPV16L1/E7 cVLP vaccine is highly immunogenic and might be protective also 
against very closely related HPV types. However, the strength of the developed response 
correlates with both the given dose- and the immune status before vaccination. 
 
 
Keywords: Cervical cancer; HPV; cVLP; therapeutic vaccination; multiplex serology;  
                        antibody; neutralization. 
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1. Introduction 
 
High-risk human papillomavirus (HPV) types are considered the major etiologic factor of 
invasive cervical cancer and its precursor lesions in women (Fehrmann & Laimins, 2003; zur 
Hausen, 2002). HPV type 16 accounts for 50-60% of the cervical cancers and high-grade 
cervical intraepithelial neoplasias (CIN II and III) and 35% of all low-grade lesions (CIN I) in 
most countries (ALTS, 2000; Bosch et al., 1995; Kulasingam et al., 2002; Moscicki et al., 
2001), followed by HPV types 18 (10-20%) and 31 and 45 (4-5% each) in cervical cancers 
(Bosch & de Sanjose, 2003; Walboomers et al., 1999). Ten further, less prevalent types are 
also classified as HR-HPV (Bosch & de Sanjose, 2003; Clifford et al., 2003a; Clifford et al., 
2003b).  
Every year, around 500,000 women develop invasive cervical cancer and approximately 
275,000 deaths per year are recorded (Parkin et al., 2005).  
In comparison to most viral infections, the natural immune response to HPV after infection is 
weak and slow (Frazer, 1996). More than 80% of HPV infections are spontaneously cleared 
(Ho et al., 1998), possibly due to cellular immune response (Frazer, 2004). However, 
inadequate immunologic control of the infection and different viral evasion mechanisms 
(O'Brien & Saveria Campo, 2002) may contribute to virus persistence and the development 
and progression of premalignant cervical lesions (Frazer, 1996; Tindle, 1996).  
The most readily detectable HPV-specific immune response is antibody formation against the 
major capsid protein L1. These antibodies appear between four months to five years after the 
first infection. However, 50% of HPV16-infected women do not develop any measurable 
capsid-specific antibody response (Carter et al., 2000).  
L1-specific antibodies are considered markers for current or previous infection (Carter et al., 
1996; Carter & Galloway, 1997; Kirnbauer, 1996) as they occur more frequently in patients 
with persistent infections or CIN III lesions than in cervical cancer patients (Nonnenmacher et 
al., 1995) and they are highly-type specific. On the other hand, antibodies to the early, non-
structural proteins E6 and E7 that are consistently overexpressed in HPV-transformed cells, 
have been found to be strongly associated with cervical carcinoma and are therefore markers 
of malignancy (Lehtinen et al., 2003; Meschede et al., 1998; Silins et al., 2002; Zumbach et 
al., 2000). The cellular immune response to the E6 and E7 oncoproteins seems to be more 
important for clearance of the infection than the humoral immune response. 
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The development of serological assays to analyze the immune response after infection with 
HPV faces some limitations including the large number of HPV types associated with 
different diseases and difficulties in isolating or producing sufficient quantities of infectious 
virions. HPV L1 protein has the intrinsic capacity to self-assemble into virus-like particles 
(VLP) (Hagensee et al., 1994; Kirnbauer et al., 1993; Zhou et al., 1991) which mimic the 
natural virions morphologically, display immunodominant conformational epitopes 
(Christensen et al., 1996a; Christensen et al., 1996b; Christensen et al., 2001) and are able to 
generate high titers of type-specific neutralizing antibodies (Schiller 1996). HPV16 VLP-
based serological assay was first established in 1994 (Kirnbauer et al., 1994) and then applied 
to other HPV types.  
Improvements in serological techniques include capture assays using bacterially expressed 
recombinant viral proteins (Sehr et al., 2001; Sehr et al., 2002) and the introduction of 
fluorescent bead-based technologies (Luminex) (Waterboer et al., 2005; Waterboer et al., 
2006). Glutathione-S transferase (GST) L1 fusion proteins were found to maintain the 
immunogenic properties of the virus particle and VLP, including presentation of neutralizing, 
linear and conformational epitopes (Yuan et al., 2001). Many systems were also established  
to develop an applicable HPV neutralization assay using athymic mouse xenografts  (Kreider 
et al., 1987), raft culture systems (Meyers & Laimins, 1994) or producing infectious HPV 
pseudovirions in vitro (Roden et al., 1996; Touze & Coursaget, 1998; Unckell et al., 1997). 
The most recent in vitro neutralization assay is based on pseudovirions carrying a secreted 
alkaline phosphatase (SEAP) reporter gene (Buck et al., 2005; Pastrana et al., 2004). 
Recently, many trials with highly effective protective vaccines have been conducted to 
prevent premalignant and malignant diseases related to infection with high-risk HPV types.  
Early preclinical trials using animal models showed that the VLP used were protective both 
against cutaneous warts as those induced by the cottontail rabbit papillomavirus (CRPV) 
(Breitburd et al., 1995; Jansen et al., 1995) and also against mucosal warts induced by the 
canine oral papilloma virus (COPV) (Suzich et al., 1995) and the oral bovine papilloma virus 
4 (BPV 4) (Kirnbauer et al., 1996). In these models, the vaccines used induced high-titers of 
serum neutralizing antibodies and protected against experimental challenge with the 
infectious virus.   
In humans, the first HPV16 VLP (Harro et al., 2001) and HPV 11 VLP (Evans et al., 2001) 
phase I vaccine trials showed that the vaccines were well tolerated and highly immunogenic 
even when administered without adjuvant and that the antibody titer in the immunized 
subjects was at least 40-folds higher than in natural infections. Recently, several clinical 
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phase II and III randomized placebo-controlled trials have been conducted. The vaccines used 
were either monovalent HPV 16 (Koutsky et al., 2002; Mao et al., 2006; Poland et al., 2005), 
bivalent HPV 16/18 (Harper et al., 2004; Harper et al., 2006), or quadrivalent HPV 
16/18/6/11 (Villa et al., 2005; Villa et al., 2006a). The vaccination results showed that these 
vaccines were well tolerated, highly immunogenic as they induced type-specific neutralizing 
antibodies, provided complete protection against persistent type-specific infections and HPV 
associated diseases and induced long-term immunity for up to 4.5 years (Harper et al., 2006; 
Villa et al., 2006b).   
Two vaccines are now commercially available, Glaxo Smith Kline’s (GSK) bivalent vaccine 
named CervarixTM and the Merck quadrivalent vaccine GardasilTM. Phase III trials of these 
two vaccines revealed that they were highly efficacious in preventing HPV 16/18 related CIN 
II/III and adenocarcinoma in situ (ASI) (FUTUREII, 2007; Garland et al., 2007; Paavonen et 
al., 2007) and high grade vulval and vaginal lesions associated with HPV 16 or HPV 18 
infection (Joura et al., 2007).  
In contrast to prophylactic vaccines which aim predominantly at inducing the humoral 
immune response, therapeutic vaccines aim at stimulating the cell-mediated immune 
response. Since VLP were unable to cause regression of established lesions, they are not 
suitable for therapeutic applications. Therapeutic vaccines focus mainly on HPV oncoproteins 
E6 and E7, as their continuous expression in infected cells is essential for the development 
and maintenance of precancerous lesions and their progression into invasive cancer (zur 
Hausen, 2002). HPV E7 protein is considered the better candidate for a therapeutic vaccine 
than E6 as it is more strongly conserved (Zehbe et al., 1998) and well immunologically 
characterized. Chimeric VLP (cVLP) are generated by the fusion of E7 to L1 (Muller et al., 
1997) and when used for immunization, they were able to induce L1-specific and neutralizing 
antibodies, to elicit an E7-specific cellular immune response and to prevent the growth of E7-
positive cells in mice (Greenstone et al., 1998; Nieland et al., 1999; Schafer et al., 1999) and 
after in vitro vaccination of human cells (Kaufmann et al., 2001). 
Recently, a randomized, double-blind, placebo-controlled phase I clinical vaccination trial 
with HPV16 L1/E7 cVLP has been conducted (CT 1006; spnsored by MediGene, Martinsried, 
Germany). The target group consisted of patients with HPV 16 positive CIN II/III. The first 
results demonstrated evidence for the safety of the vaccine and a non significant-trend for 
clinical efficacy. The trial showed that the vaccine is able to induce L1 and E7 specific 
antibodies and also a cellular immune response (Kaufmann et al., 2007).   
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The aim of the current study is to analyze the details of the humoral immune response induced 
after vaccination with HPV16 L1/E7 cVLP. We analyzed the induction of HPV16 L1-specific 
as well as E7-specific antibodies. Moreover, we investigated the induction of L1 or E7 cross-
reactive antibodies to other HPV types, induction of antibodies to other HPV 16 early proteins 
(E6, E4, E2 and E1) and finally whether the particles are able to induce protection by 
neutralizing antibodies.  
 
 
2. Methodology 
 
2.1 Study design and vaccine 
The present 24 week, multi-center, double-blind, placebo-controlled phase I immunogenicity 
trial was spnosored by MediGene (Martinsried, Germany). Serological analyses presented 
here were conducted at the German Cancer Research Center in Heidelberg, Germany. 
Thirty-six women histologically diagnosed as CIN II or III patients were recruited for this 
study. They were all HPV 16 DNA positive and negative to any other high-risk type. Details 
about the selection criteria and disease profiles of these subjects were previously published 
(Kaufmann 2007). The same report describes in details the properties of the administered 
vaccine. Briefly, it consists of highly purified HPV 16 L1/E7 cVLP (Mueller 1997) given 
intramuscularly without adjuvant. The enrolled patients were divided randomly into three 
groups of each 12 patients. The first group received placebo, the second group received 75 µg 
(low-dose) and the third group received 250 µg (high-dose) of the vaccine. Four vaccine 
injections of the same dose were given at weeks 0, 2, 6, and 12. Blood samples for serology 
were collected at baseline and at weeks 2, 4, 8, 14, and 24.  
 
2.2 Multiplex serology 
Specific antibody responses to HPV 16 L1 and E7 were analyzed. Additionally,  L1-reactive 
antibodies to 27 other HPV types belonging to 17 different species were analyzed (HPV 31, 
33, 35, 52, and 58 (α9); HPV 18 and 45 (α7); HPV 6 and 11 (α10); HPV 2 and 57 (α3); HPV 
3, 10, and 77 (α2); HPV 32 (α1); HPV 49 (β3); HPV 15 and 38 (β2); HPV 92 (β4); HPV 5 
(β1); HPV 4 (γ1); HPV 50 (γ2); HPV 48 (γ3); HPV 60 (γ4); HPV 41 (nu); HPV 1 (mu1) and 
finally HPV 63 (mu2)), as well as E7-reactive antibodies to 8 other types of 3 different 
species (HPV 31, 33, 35, 52, and 58 (α9); HPV 18 and 45 (α7) and HPV 6 and 11 (α10)). The 
detection assay used is based on expression of all L1 and E7 full-length proteins (with HPV 
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6b, 16, and 18 L1 lacking 10 amino acids at the N-terminus) as double fusion proteins with N-
terminal Glutathione S-transferase (GST) and a C-terminal undecapeptide (tag) of the SV40 
large T-antigen (Sehr 2001, 2002) in combination with multiplex bead-based technology 
(xMAP, Luminex Corp, Austin, Texas) (Waterboer et al., 2005 and 2006). Briefly, 
glutathione cross-linked to casein was cross-linked to different fluorescence-labeled 
polystyrene beads (SeroMap, Luminex, Austin, TX). Beads sets of different colors were 
individually loaded with different GST-tag fusion proteins. The beadmix was then incubated 
with serum diluted 1:100  for E7 assay and with three-fold dilutions starting at 1:100 for L1 
antigens. Antibodies bound to the beads were stained by biotinylated anti-human-Ig and 
streptavidin-R-phycoerythrin. Beads were analyzed in a Luminex 100 analyzer that identifies 
the bead color and quantifies the antibodies bound to the viral antigens as previously 
described (Waterboer 2005).  
 
2.3 Neutralization assays 
In vitro HPV 16, 18, and 11 neutralization assays based on HPV pseudovirions carrying a 
secreted alkaline phosphatase (SEAP) reporter gene were carried out as previously described 
(Buck et al 2005, Pastrana et al 2004). Screening for neutralizing antibodies was performed 
by infecting 300,000 293TT cells/ml with the different HPV pseudovirions in the presence of 
sera diluted 1:20. Infections were performed 5-6 h after seeding of the cells. Untreated cells, 
cells treated with pseudovirions alone or cells treated with pseudovirions in the presence of a 
known type-specific neutralizing serum were used as controls. Five days after infection, the 
supernatants were assayed for presence of SEAP using a chemiluminescent SEAP Reporter 
Gene Assay (Roche Diagnostics, Mannheim, Germany). When neutralizing, the endpoint 
neutralization titers were determined by titrating the neutralizing sera against the neutralized 
pseudovirus type.  
 
2.4 Statistical analyses 
In all multiplex serology experiments, antibody reactivity against GST-tag without 
intervening viral sequence was used to define the background. The net median fluorescence 
intensity (MFI) was obtained by subtracting the background reactivity from the reactivity 
against the viral fusion proteins. Sera were classified positive at a given dilution if the net 
MFI value was greater than or equal to 150 and 50 in L1 and E7 serology, respectively.  
In neutralization assays, net relative light units (RLU) were calculated by subtracting RLU of 
untreated cells (background) from RLU of cells treated with the serum/pseudovirion mixture. 
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The endpoint neutralization titer was defined as the last dilution yielding ≥70% reduction in 
the SEAP activity in comparison to the reactivity of the pseudovirions added without serum. 
The multiplex serology and neutralization titers are given as the reciprocal of the highest 
dilution showing positive signals for each assay. 
Specific response due to vaccination was defined as a two-fold or higher increase in the 
antibody reactivity or titer in any week after vaccination relative to the response at baseline 
(W0). For L1, cross-reactivity was counted when titer difference was equal to three-folds in 
two consecutive sera or > 3-fold in at least one serum. For E7 cross-reactivity, two-folds or 
more differences in MFI values were considered significant.   
The Wilcoxon signed rank sum test was used to compare the distribution of antibody titers or 
MFI between different timepoints within and between specific vaccine groups. The same test 
was also used to evaluate the cross-reactivity within or between the different vaccine groups. 
P-values <0.05 were considered statistically significant. Multiplex serology and neutralization 
assays were directly compared using Kappa statistics. All analyses were performed with SAS 
Statistical Package version (9.1). 
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3. Results 
 
3.1 Vaccination with HPV16 L1/E7 cVLP induces HPV16L1 antibodies 
At baseline (week 0, W0), HPV16 L1 antibodies were present in twenty-one (58%) of the 
study participants. None of the placebo recipients seroconverted or increased the reactivity 
towards L1. All vaccinees showed an increased HPV16 L1 antibody response already at W2, 
visible both as strongly increased MFI values at 1:100 serum dilution and end-point dilution 
titer, 134-fold for the high-dose and 45-fold for the low dose group. (p<0.001 for both). There 
was a linear relationship of end-point titer (titers 100 to 81000) and MFI values at 1:100 (MFI 
155 to 9344) (Figure 1, Table 1). 
Among high-dose recipients the geometric mean titer did not change until W14 while low-
dose recipients continued to increase antibody titer at lower rate, reaching similar level as the 
high dose group at W14. At W24 the titer decreased 2.5- to 3-fold in both groups (Figure 1C).  
Vaccinees baseline seronegative, at W2 reached a GMT of 2.2 only while the seropositives 
starting from 827 reached 67 (30-fold difference). At W14 the GMT in baseline seronegatives 
increased to 19.9 thus nearly reaching the GMT of 56.6 in the baseline seropositives (3-fold 
difference). 
 
3.2 HPV16 L1 neutralizing antibodies are induced upon vaccination 
At baseline 16 participants (44%) had neutralizing antibodies (Table 1). None of the placebo 
recipients developed additional neutralizing antibodies. While 8 of the vaccinees developed a 
very weak response (boarder-line titers) over time, 16 showed strong response. For the later 
group, the increase in the neutralization titer was observed already at W2, the low-dose group 
reaching (GMT 661) a 1.8-fold lower level than the high-dose group (GMT 1159). At W14, 
the titer doubled among the low-dose recipients and tripled in the high-dose group; but at 
W24 already decreased 5- and 3-fold, respectively, in both groups (Table 1).  
Vaccinees baseline neutralization negative, at W2 reached a GMT of 283 only while the 
seropositives starting from 104 reached 487. The titers and the group difference did not 
change at W4 and W8, but with the increase at W14 the titer among baseline negatives 
became slightly higher than among the baseline positives, at W24 both fell to very similar low 
levels (182 and 187, respectively). 
 
Neutralization titers correlated with the Luminex titers (kappa=0.618; 95% CI 0.304-0.932), 
indicating that in vaccinees Luminex titers are valid proxies for neutralizing antibodies 
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(Figure 2B). For natural antibodies, this correlation could not be applied (unpublished 
observation). 
At baseline, three and one patients had natural neutralizing antibodies to HPV 11 and HPV 
18, respectively. However, none of the vaccine recipients developed cross-neutralizing 
antibodies to HPV 11 or HPV 18 pseudovirions. 
Neutralizing antibodies are expected to correlate most closely with the vaccine’s potential for 
protection. 
 
3.3 Vaccination induces L1 cross-reactive antibodies  
Although the vaccine used in this study was composed of L1 and E7 proteins of HPV 16, it 
was able to induce cross-reactive antibodies frequently to mucosal alpha types, and rarely to 
cutaneous alpha, beta, gamma, mu and nu types.  
Induced cross-reactivity was observed in sera baseline seronegative to any other HPV types 
than HPV 16 and seroconverting after vaccination or baseline seropositive and increasing 
reaction.    
In the placebo group, none of the patients showed any cross-reactivity. The reactions with 
other HPV types than 16 remained stable over time. All vaccinees seroconverted to at least 
one of the other HPV types analyzed here irrespective of vaccine dose (Figure 3A).  
The kinetics of cross-reactive antibody formation was slightly delayed, especially in low-dose 
in comparison to that of HPV 16 L1 antibodies. The median time point of cross-reactivity 
seroconversions in patients of the high-dose group was W2 versus W4 in the low-dose group. 
At this week, the response plateau in most of the patients was reached. 
Cross-reactivity titers (median 100, range 100 to 8100 in the low-dose group; median 100, 
range 100 to 218,700 in the high-dose group) were lower than HPV 16 specific titers (median 
8100; range 100 to 218,700 in low-dose group versus median 24,300; range 900 to 218,700 in 
high-dose group). These differences were statistically significant (p<0.050 for all types) 
(Figure 3B, C). 
Cross-reactions to alpha mucosal types were the strongest and most frequent in both groups. 
From the high risk types, HPV 31 followed by HPV 35 and 33 were the most frequent types 
(100% of seroconverted vaccinees).The least frequently recognized HR-HPV were HPV 52 
and 58 (83%). Despite belonging to a different and phylogenetically distant species, cross-
reactive antibodies to HPV 18 and 45 were also very frequent (100%) in both vaccine groups.   
In the high-dose group, the low-risk types HPV 11 and HPV 6 were less frequent than the 
high-risk types. In the low-dose group, frequency of HPV 11 was higher. 
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Generally, seropositivity to skin HPV type was least frequent (62% and 26% in high-dose and 
low-dose groups, respectively). 
Cross-reactivity was more frequent in the high-dose recipients than in the low-dose recipients; 
the mean of the number of cross-reactive types was 19 and 14 in the both groups, 
respectively.  
In conclusion, vaccination with HPV16 L1/E7 cVLP induces intra- and inter-species cross-
reactive antibodies.      
 
3.4 Vaccination induces HPV16E7 specific antibodies 
At study entry, only six patients (17%) had natural anti-HPV16E7 specific antibodies (median 
110 MFI; range 51 to 636). The W0 HPV 16E7 response in the placebo recipients did not 
change over time. All vaccinees except one of the low-dose group developed an immune 
response to HPV16E7 (Figure 4A). 
The median time of serconversion in both vaccine groups was W2. The increase in HPV16E7 
response in both vaccine groups continued after W2 (Figure 4B). 
At any time after W2, reactivity to HPV16 E7 was stronger in high-dose recipients (GM 592 
MFI; range 290 to 1222) than in low-dose recipients (GM 119 MFI; range 56 to 253). The 
differences between the two groups were statistically significant (p=0.003) (Figure 4B). On 
the other hand, at W2, the response to HPV 16 E7 was 20- and 75-folds weaker than that 
observed for HPV 16 L1 response in term of MFI values in high-dose and low-does groups 
respectively. 
The immune response in patients who had natural HPV16E7 antibodies at W0 was 3.4-fold 
higher than in patients with no detectable natural antibodies at baseline. 
 
3.5 Vaccination induces HPV16E7 cross-reactive antibodies 
Among the placebo recipients, two showed single seropositivity (HPV 33 and 45) at W2 or 
W24 with ≥2 folds response. Among vaccines, HPV E7 cross-reactive E7 antibodies to at 
least one other type than HPV 16 were induced in 13 (54%, 5 low-dose and 8 high-dose) of 
the 24 vaccinees (Figure 5). Time of seroconversions was later (after W4) than for HPV 16 
E7 antibody response (W2). 
The response to any of the cross-reactive types (MFI median 154, max 3018, min 50) was 
weaker than to the specific immune response to HPV16E7 (MFI median 291, max 8207, min 
51). However, only for HPV 35, differences in cross-reactivity strength between the two 
vaccine groups were statistically significant (p<0.02).  Multiple positivity was more frequent 
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in high-dose group than the low-dose group. Cross-reactivity followed the phylogenetic 
classification as most frequent cross-reactions (19% of all) were detected with the closely 
related HPV types of the α9 species. It was more frequent in the high-dose group than in the 
low-dose group (Figure 5A). In the high-dose group, HPV 31 was the most frequent cross-
reactive type (50%), followed by HPV 35 (42%) and HPV 33 (33%). The least cross-
reactivity frequency was observed with HPV58 (17%). No cross-reactions to any α7 or α10 
types were recorded. In the low-dose group, HPV 31 was again the most frequent cross-
reactive type (18%). Frequencies for HPV 35, 33, 58, 45, and 6 were low (9% each). No 
cross-reactive antibodies to HPV18E7, 11E7 or 52E7 were detected. 
 
3.6 Vaccination induces an immune response to other early HPV16 proteins 
While none of the placebo or high-dose groups were positive at study entry to any HPV 16 
early proteins other than E7, two patients of the low-dose group were positive to both E2 and 
E4. The response to HPV 16 other early proteins among placebo remained stable over time. 
Upon vaccination, seven and six patients of the high-dose and low-dose groups respectively 
developed antibodies to at least one other early protein; E6, E2, E4 or E1 (Figure 6).   
Time of seroconversion (W8 or later) in the three study groups to any of these early proteins 
occurred later than time of seroconversion  of HPV 16 E7 or L1. Antibodies to HPV16 E6 
were most frequent, followed by E4 and E2 and E1.    
There were no statistically significant differences between the responses induced in both 
vaccine groups at W2 or later (p>0.05). 
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4. Discussion: 
 
HPV16 is the most common associated type with cervical cancer (Bosch et al., 1995; 
Walboomers et al., 1999) and the most commonly detected HPV type in most epidemiologic 
studies (Cates, 1999; Koutsky, 1997). Several clinical trials have been conducted to evaluate 
HPV prophylactic vaccines consist of virus-like particles (VLP). As alternative to VLP, 
chimeric VLP were generated mainly to develop a vaccine that combines prophylactic and 
therapeutic properties. They are consisting of a C-terminally truncated L1 protein fused to 
sequences of the HPV16 E7 oncoprotein (Jochmus et al., 1999). 
 
This study aimed to analyze in detail the immune response after vaccination with 
HPV16L1/E7 cVLP vaccine (Kaufmann et al., 2007). We investigated the induction of 
HPV16 L1 specific antibodies and also cross-reactive antibodies to L1 of other HPV types 
(n=27) including mucosal and skin types of different species (alpha 1, 2, 3, 7, 9, 10, beta 1, 2, 
3, 4, gamma 1, 2, 3, 4, Mu 1, 2, and Nu) using Luminex multiplex technology (Waterboer et 
al., 2005; Waterboer et al., 2006). We also analyzed the type-specific and cross-reactive 
immune response to HPV16E7 oncoprotein. Additionally we extended the study to detect any 
immune response to other HPV16 early proteins including E6, E1, E4 and E2. Neutralizing 
antibodies against HPV16, 18 and 11 were analyzed using the in vitro neutralization assays 
based on HPV pseudovirions carrying a secreted alkaline phosphatase (SEAP) reporter gene 
(Buck et al., 2005; Pastrana et al., 2004). 
 
The importance of this study is due to the fact that the patients received the vaccines are CIN 
II or III patients; so that we have data of antibody response to natural HPV infection. This 
allowed us to comment on the antibody response following immunization relative to that seen 
after acquisition of an HPV infection. All responses after vaccination were only due to the 
vaccine and not to any new infection. This is because antibodies due to a new infection need a 
long time to be detected in the patient serum. 
As previously described (Jochmus et al., 1999), cVLP can function as an intrinsic adjuvant. 
This give the current vaccine the advantage of being administered without use of any adjuvant 
in contrast to many other vaccine trials done so far; thus the immune responses detected after 
vaccination is only due to the vaccine components. 
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In general, virus-like particles (VLP)-based vaccines are thought to be safe. These particles 
are morphologically and immunogenically similar with the natural HPV virions, but contain 
no DNA which makes them non-infectious.  
 
Although all the patients enrolled in this study are infected with HPV16, but for some patients 
no HPV16 antibodies were detected. It might be that these women had lost the antibody 
responsiveness either due to the loss of L1 expression following integration of the viral DNA 
into the host cell genome, or because of changes in immune function resulting from lesions 
formation or therapy.  
 
HPV16L1/E7 cVLP vaccine is highly immunogenic. All participants who received the 
vaccine developed high titers of HPV16 L1 specific antibodies (around 100 folds or higher 
than what observed in natural infection represented by W0) out to week 24. These results are 
in agreement with previous clinical trials based on VLP-vaccines (Fife et al., 2004; Harper et 
al., 2004; Koutsky et al., 2002; Villa et al., 2005; Villa et al., 2006a).  
So far, neutralization assays are often considered to be the “gold standard” in assessing the 
immunogenecity of a prophylactic vaccine, so that the clinical significance of any vaccine 
trial is related to its ability to induce neutralizing antibody response. The data presented here 
showed that all of the HPV16L1/E7 cVLP vaccine recipients induced neutralizing antibodies 
giving it the properties of a successful prophylactic vaccine. 
 
Data showed that neutralizing antibodies can be detected when the patient has a strong MFI 
signals (>450-700) giving an indication that Luminex is more sensitive than neutralization 
assay. However, technically there were a good correlation between HPV 16L1 Luminex titers 
and neutralization titers at 1:100. Such a correlation gave us the opportunity to analyze  the 
possibility of using the Luminex readout MFI values at 1:100 as a surrogate to define or 
calculate the antibody and /or neutralizing titer of any serum, for example in case of having a 
limited volume of the serum for such analyses. Moreover, this correlation held for individuals 
as well as for the two vaccine groups, implying again that the Luminex appears to represent 
an appropriate surrogate assay for the neutralization assay.  
 
Although all the vaccine recipients developed specific HPV16 L1 antibodies by two weeks 
after the initial immunization, but two factors had impact on the strength of the immune 
response developed. First, the dose of the given vaccine correlates with the reported immune 
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response. When a high dose (250µg) of the vaccine was given, the antibody titers were very 
high; all the baseline seronegative patients became positive and reached saturation at week 2 
post vaccination. In contrast the response was lower (2-4 folds) and slower when less vaccine 
dose (75µg) was given. In this group, the antibody saturation was reached later at W14. A 
similar correlation has been described previously (Fife et al., 2004).    
A second factor was the immune status of the patients before receiving the vaccine. It seems 
that in CIN II or III patients, preexisting of HPV 16L1 antibodies at baseline influences the 
immune response after vaccination. Other clinical vaccine studies (Harro et al., 2001; 
Koutsky et al., 2002) have reported a similar finding; increase in antibody titers in subjects 
who were seropositive before vaccination. This might be due to formation of memory 
immune response to L1 capsid protein which helps in responding quickly to a new infection 
(cVLP particles in the vaccine). This memory immune response has been discussed in details 
by Olsson and colleagues (Olsson S. E. et al 2007).  
In comparison to the response detected by Luminex, only the vaccine dose had a significant 
influence on the neutralizing antibody titers as higher vaccine dose resulted on higher 
neutralizing titers (up to 3,4 fold differences). 
 
A wide inter- and intra- cross-reactivity patterns were reported by Luminex as many of the 
vaccine recipients had L1 antibodies to at least 7 types other than HPV16. This was expected 
since GST-L1 fusion proteins which are used as Luminex antigens have been shown to 
exhibit cross-reactive and non-neutralizing linear epitopes as well as conformational epitopes 
(Rizk et al 2007). Cross-reactivity follows loosely the phylogenetic grouping. The most 
frequent cross-reactivity was with the closely related HPV types in species alpha 9, followed 
by alpha 7 and alpha 10. However, some patients also cross-reacted with non-related HPV 
types including the cutaneous types.  
In contrast, no cross-neutralizing antibodies have been detected after vaccination; which is 
also in agreement with the fact that neutralizing antibodies are directed against L1 
conformational epitopes that are mostly type-specific. Based on these findings, we think that 
neutralization assays could be more genotype-specific than luminex. For example, sera from 
patients with very high HPV16L1 antibody titers did not neutralize HPV18 or HPV11 
paeudovirions, although the same sera were cross-reactive in Luminex with both HPV types. 
Cross-reactivity when present correlates with the number of vaccine doses; the more the doses 
the patient receives the more cross-reactivity to be observed. Moreover, HPV 16 L1 specific 
titers were higher than the cross-reactive titers (≥100 fold differences). This observation has 
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been previously described (Wideroff et al., 1995). This might be because upon every vaccine 
dose administered, the cVLP are accumulated and possibly increase the chance of occurrence 
of cross-reactive epitopes that may be present on the surface of other HPV types.  
 
So far, cVLP in mice were found to induce HPV16E7-specific antibodies (Muller et al., 
1997). In this clinical study, vaccination with cVLP induced HPV16E7 specific antibodies as 
well. The responses in comparison with HPV16L1 antibodies were lower. A previous clinical 
study used HPV16E7 protein-based vaccine showed also that HPV16E7 antibody titers were 
low (Hallez et al 2004). The reason for lower E7 antibody response could be that L1 in the 
particles is present in a higher proportion than E7 or it is more exposed to the immune system. 
E7 cross-reactivity followed exactly the phylogenetic grouping. All cross-reactions were 
within types of the species alpha 9. Only in one case, a cross-reaction with HPV6 (alpha 10) 
was observed, however the response was extremely weak and just above the cut-off used to 
differentiate between positivity and negativity. Not all patients exhibited cross-reactive L1 
antibodies showed also cross-reactivity to E7. The different structural properties and size of 
both proteins may explain why cross-reactivity to L1 was more frequent than to E7. As for 
L1, cross-reactivity to E7 correlated with the number of vaccine doses given to the patients.   
 
The peak of antibody response after administration of the cVLP vaccine was reached directly 
after the first vaccination dose (at W2) followed by stable response until W14 where a slight 
increase in the response is observed (for neutralizing antibodies the response at W14 was very 
strong forming a second clear immune response peak). Afterwards a decline in the antibody 
level was generally observed. Serum antibody responses in baseline seropositive patients 
increased faster and peaked at higher levels than the responses in baseline seronegative 
patients. This response pattern is highly suggestive of an anamnestic response to the HPV16 
antigens (L1 and E7). Typically, the immune responses decrease with time after antigen 
stimulation because absence of the antigen leads to removal of the stimulus for further 
antibody production. Moreover, plasma cells have a limited lifespan which means that 
production of antibodies would only due to presence of memory B cells (Olsson et al 2007). 
Unfortunately, we were unable to analyze the persistent of the induced antibodies after 24 
weeks due to the short study duration and there were no follow-up sera collected from the 
patients enrolled in this study. 
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In preliminary analyses done on patients receiving this vaccine, no responses were detected 
against HPV16 E1, E2 or E6 (Kaufmann et al., 2007). In contrast we found that certain 
immune responses to E6, E2, E1, and additionally to E4 have been developed and increased 
as more vaccine doses are given. An explanation for this unexpected response induction could 
be the nature of the vaccine. The vaccine itself may have a cytopathic effect on the cells and 
induce a cellular immune response causing the release of these early proteins and increase the 
chance of their exposure to the immune system. In the cells, viruses are still active in DNA 
transcription and replication. This event is important as it might indicate that administration of 
this vaccine could by induction of these early proteins share partly in stimulating the 
regression of the developed lesions due to the infection.   
 
In conclusion, the results obtained in this study support that HPV16 L1/E7 cVLP vaccine has 
the properties of a prophylactic vaccine as it induce L1-binding, -neutralizing and additionally 
E7-specific antibodies. Induction of other early proteins might improve the suitability of the 
analyzed vaccine as a therapeutic vaccine to be given to already infected women.  
Several preclinical studies used HPV16L1/E7 cVLP demonstrated the induction of E7-
specific CTL that are able to inhibit tumor growth in mice (Greenstone et al., 1998; Jochmus 
et al., 1999; Schafer et al., 1999). Therefore, more clinical studies to the cellular-immune 
response induced after vaccination with the cVLP should be conducted in order to give a clear 
and complete picture about this vaccine. If the suitability of cVLP to be used as prophylactic 
and at the same time as therapeutic vaccine has been proved in human, then these particles 
could be more advantageous over VLP used recently as only prophylactic vaccines and they 
may be applicable in women already infected.  
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 Figure legends: 
 
Figure 1  
Immune response of patients vaccinated with HPV16L1/E7 cVLP. Each 12 CIN II/III 
patients were immunized with placebo or low dose (75µg), or high dose cVLP (250µg) at 
weeks 0, 2, 6, and 14. Blood samples for serology were taken at weeks 0, 2, 4, 8, 14, and 24. 
(A) Box plots of HPV16L1 reactivity in median fluorescence intensity (MFI) units. The 
dashed horizontal lines represent the seropositivity cut-off (150 MFI). (B) Correlation 
between MFI values at 1:100 dilution and endpoint dilution titers, defined as the highest 
serum dilution resulting in a signal above the cut-off (150 MFI). N on the x-axis represents 
the seronegative sera, titer<100 (C) Levels of HPV16L1 antibodies over time. The geometric 
mean titers and the 95% confidence intervals are shown throughout the 24 weeks of the study. 
Each line represents a different treatment group. Stars indicate the times of vaccination.  
 
Figure 2 
Vaccination with HPV16L1/E7 cVLP induces neutralizing antibodies. 
Sera collected from low and high doses vaccine recipients were analyzed for presence of 
neutralizing antibodies to HPV16 pseudovirions using the in vitro SEAP assay. Serum 
neutralization titers were also determined and were defined as the reciprocal of the highest 
dilution that caused at least a 70% reduction in SEAP activity. (A) Neutralization titers at W0 
compared to W14. Dashed horizontal line represent the positivity cut-off (B) For each serum, 
neutralization titers were plotted against luminex binding antibody titers. N represents the 
group of seronegatives (titer<100, on x-axis) or the non-neutralizing sera (titer<60, on y-axis).  
 
Figure 3 
Vaccination with HPV16L1/E7 induces L1 cross-reactive antibodies.  
Study participants were investigated for the presence of L1 cross-reactive antibodies to 
different HPV types other than HPV16 (types grouped as alpha mucosal, alpha cutaneous and 
skin). (A) number of participants who seroconverted to any other HPV L1 within each group 
were counted in the different vaccine groups. Color codes are in the inserted legend. Cross-
reactive antibodies were titrated and the geometric mean titers of the three different cross-
reactive groups was calculated and compared to that of HPV 16 in (B) low-dose group and 
(C) the high-dose group. Stars indicated the times of vaccination. 
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Figure 4 
Vaccination with HPV16L1/E7 cVLP induces HPV16 E7 antibodies. 
Sera were investigated for the presence of E7 specific antibodies. (A) Box plots of HPV16E7 
reactivity in median fluorescence intensity (MFI) units. The dashed horizontal lines represent 
the seropositivity cut-off (50 MFI). (B) Levels of HPV16E7 antibodies over time. The 
geometric mean titers and the 95% confidence intervals are shown throughout the 24 weeks of 
the study. Each line represents a different treatment group. Stars indicated the times of 
vaccination. 
 
Figure 5 
Vaccination with HPV16L1/E7 induces E7 cross-reactive antibodies.  
Patients were investigated for the presence of E7 cross-reactive antibodies to different HPV 
types belonging to different alpha species (7, 9 and 10). (A) Number of participants who 
seroconverted to any other HPV E7 within each species was counted in the different vaccine 
groups. Color codes are in the inserted legend. Levels of E7 cross-reactive antibodies 
represented by the geometric mean of the MFI values were calculated and compared to that of 
HPV16 in (B) low-dose group and (C) the high-dose group. Stars indicated the times of 
giving the vaccine. 
 
Figure 6 
Vaccination with HPV16L1/E7 induces other HPV 16 early proteins. 
Sera were investigated for the presence of any immune response to other HPV16 early 
proteins including E6, E1, E2, and E4. Number of participants who developed increased 
immune reponse to any of these was counted among the three vaccine groups. E6 was the 
most frequent type, followed by E4, E1 and finally E2. 
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Table 1 Summary of the immune responses to HPV16 L1 and E7 throughout 24 weeks after 
vaccination with HPV16L1/E7 cVLP  
Placebo Low-dose High-dose
Antigen week Luminex Neutralization Luminex Neutralization Luminex Neutralization
median1 range median range median range median range median range median range
HPV16L1 W0 200 30-2700 40 20-180 65 30-2700 20 20-180 200 30-2700 20 20-180
W2 100 30-2700 8100 300-218700 210 20-8100 72900 900-218700 720 60-2700
W4 300 30-2700 8100 100-218700 110 20-2700 72900 900-218700 720 20-2700
W8 200 30-2700 8100 2700-218700 180 20-2700 24300 2700-218700 240 60-1800
W14 200 30-2700 40 20-180 24300 8100-218700 390 130-5400 24300 8100-218700 585 130-48600
W24 100 30-900 8100 2700-218700 150 60-2700 16200 2700-218700 110 20-8100
HPV16E71 W0 13 1-370 15 6-137 27 8-636
W2 18 5-312 57 25-11062 793 39-2365
W4 12 6-492 108 14-4007 657 131-5820
W8 18 6-536 128 39-2562 557 186-5930
W14 15 4-212 115 13-2089 823 65-8207
W24 14 8-398 80 20-1602 435 29-7903
 
1
 For HPV16E7, MFI values are shown 
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Rizk et al, Figure 2 
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Rizk et al, Figure 3 
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Rizk et al, Figure 4 
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Appendix 1 
 
Anti-tag ELISA 
Quality and quantity of MBP-16L1tag fusion proteins were investigated using anti-tag 
ELISA. MBP-16L1tag obtained from E.coli strain Rosetta was titrated in a 1:3 dilution steps 
on a plate coated with 100 µl/ml amylose and identified using mouse anti-tag monoclonal 
antibody. As a positive control for this experiment, GST-tag and GST-16L1tag fusion protein 
were titrated in parallel on a plate coated with 200 ng/ml glutathione-casein as capture 
protein. The antigen titration curves showed that MBP-16L1tag was expressed in full length 
and that its curve goes in parallel with those of GST-tag alone or GST-16L1tag fusion 
protein. MBP-16L1tag reached the saturation plateau earlier (at 3 µg/ml) than MBP-16L1tag 
(at 8 µl/ml).  
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Figure 1. Titration curves of MBP16L1tag. ELISA plates coated over night (4oC, 100µl/well) with 
either 100 µg/ml amylose or 200 ng/ml glutathione casein were incubated with different 
concentrations of: MBP16L1tag expressed in E.coli Rosetta strain. GST-tag and GST16L1tag were 
titrated in parallel as a control. The bound protein to amylose was detected via the C-terminal tag 
epitope by mouse anti-tag monoclonal antibody. Absorbance values were expressed in milliunits 
(mA).  
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Appendix 2 
 
Validation of MBP-16L1 using monoclonal antibodies  
Quality of MBP-16L1tag as ELISA antigen was estimated by direct comparison with GST-
16L1tag. For this aim, the reactivity of 29 previously defined monoclonal antibodies 
generated against HPV16 VLP was analyzed with MBP-16L1tag and GST-16L1tag in 
parallel. Absorbance value pairs obtained with the two ELISA systems for each monoclonal 
antibody were compared in xy plot (Figure 2A). Comparison showed agreement of the two 
result sets with linear regression R2 value of 0,77. A kappa value of 0,473 (95% CI range 
from -0,232 to 1,178) was found which indicated that the strength of agreement between the 
two ELISA formats is considered to be moderate.     
 
Validation of MBP-16L1 using human sera  
In a second experiment to validate MBP-16L1tag as ELISA antigen, 72 sera from 36 patients 
clinically diagnosed with cervical intraepithelial neoplasia CIN (grade II or III) and enrolled 
in a Medigene HPV16L1/E7 cVLP vaccination study were analyzed by both GST-16L1tag 
and MBP-16L1tag ELISA. For each patient a pre- and a post-vaccination serum were 
analyzed. Comparison of the two ELISA data revealed a high correlation with R2 value of 
0.95 and kappa value of 0.806 (95% CI range from 0,669 to 0,942) which indicated that the 
strength of agreement is considered to be very good (Figure 2B). 
In summary, the validation experiments proved that MBP-16L1tag can react efficiently as 
well as GST-16L1tag does with HPV16L1 specific antibodies of different sources (mice and 
human). This indicated that fusing MBP to HPV16L1 had no effect in the folding of the 
protein and therefore on the presentation of the different epitopes. 
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Figure 2. Validation of MBP16L1tag as ELISA antigens. Reactivity of (A) HPV16L1 specific 
monoclonal antibodies generated against HPV16 VLP and (B) human sera from HPV16L1/E7 cVLP 
Medigene vaccination study determined by GST-16L1tag and MBP-16L1tag ELISA. For each 
monoclonal antibody or serum, result from GST-16L1tag ELISA is plotted on x-axis and that from 
MBP-16L1tag ELISA on y-axis. Values are given in mAU (milli absorbance unit). The linear 
regression line and the R2 value as measure of assay agreement are given.   
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Appendix 3 
 
Titration of MBP-16L1tag blocking activity 
After validation of MBP-16L1tag fusion protein as ELISA antigens, the next question was; at 
which concentration can the MBP-16L1tag block HPV 16 specific- and/or cross-reactive 
positive signal of a mAb and then of a human serum. To answer this question, the blocking 
activity of the MBP fusion protein was titrated against type-specific and cross-reactive mAb 
and also against different human sera with different reactivity patterns.     
 
Titration of MBP-16L1tag blocking activity using monoclonal antibodies  
To determine the appropriate MBP-16L1 concentration that could be used to block HPV16 
specific and cross-reactive epitopes, MBP-16L1 fusion protein blocking activity was titrated 
using different HPV 16 mono-specific and cross-reactive monoclonal antibodies. The 
following antibodies were used in these experiments: 
 
H16.5A strongly reactive with HPV16 but not HPV18 
H16.9A strongly reactive with HPV16 and weakly with HPV18 
H16.H5 strongly reactive with HPV16 and intermediate with 
                                    HPV18 
H16.8B strongly reactive with both HPV16 and 18 
 
In the first experiment, the mAb all diluted 1:2500 were preincubated with different 
concentrations of MBP-16L1 starting from 4 µg/µl and diluted in 1:2 steps down to 0,0 µg/µl. 
GST-tag was always used as a negative control.  
As expected after the preabsorption step, all of the four monoclonal showed different degrees 
of inhibition in their reactivity when examined further with GST-16L1. The reactivity of 
H16.8B and H16.H5 was reduced by ≥70% when preabsorbed with 0,125µ/µl MBP-16L1. 
H16.5A showed 70% reduction in reactivity at MBP-16L1tag concentration of 0,25 µg/µl. 
The least monoclonal antibody to loose binding activity to GST-16L1 was H16.9A which 
achieved 70% reduction in its activity when preabsorbed with 0,5 µg/µl MBP-16L1 (Figure 
3A). The same mAb were further examined with GST-18L1 in order to ensure the specificity 
of the assay and also to investigate if the cross-reactive epitopes recognized by three of these 
mAb can be also blocked by MBP-16L1 preabsorption step. The specificity was achieved as 
in absence of MBP-16L1, H16.5A did not react with GST-18L1, whereas H16.8B reacted 
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very strongly and H16.9A and H16.H5 reacted very weakly as expected. After preabsorption 
with MBP-16L1, more than 90% blocking in the reactivity of the later three mAb was 
achieved at a concentration of 0,125µg/µl (Figure 3B). 
The common observation in this experiment was the fast and direct decrease in the reactivity 
of the mAb at the lowest MBP-16L1 concentration used for the preabsorption (0,125µg/µl). 
However, we were interesting in investigating how would be the decrease in reactivity if 
using smaller concentrations than 0,125µg/µl; therefore a second experiment was performed 
using lower concentrations of MBP-16L1. The same mAb used in the first experiment were 
preincubated with different concentrations of MBP-16L1 starting from 3 µg/µl and diluted in 
1:3 steps down to 0,0 µg/µl. A nice sigmoidal reactivity titration curves were obtained. Up to 
an MPB-16L1 concentration of 0,1µg/µl retained H16.5A most of its binding activity 
(≥90%). The other cross-reactive mAb H16.9A, H16.H5 and H16.8B hold ≥80% of their 
reactivity only up to 0,01µg/µl of MBP-16L1; they lost their binding activity faster than the 
mono-specific H16.5A. The data showed also that at MBP-16L1 concentration of at least 
1µg/µl, all the specific and cross-reactive epitopes can be blocked, however, blocking of 
cross-reactive epitopes can be achieved using less amount of the MBP-16L1 (Figure 3C). 
When testing the mAb with GST-18L1, again only the strongly cross-reactive H16.B8 
showed a significant signal. In comparison to the binding activity to HPV16, most of the 
reactivity (>90%) to HPV18 (cross-reactive type) inhibited by using at least 0,03µg/µl 
(Figure 3D) which is 27 folds lower than the amount necessary to block reactivity to the 
specific HPV type.  
From theses experiments we concluded that using at least 1µg/µl is sufficient to block both 
reactivity to the type-specific as well as the cross-reactive epitopes.  
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Figure 3 (continued). Titration of MBP16L1 blocking activity using monoclonal antibodies. Four 
mAb were preincubated with MBP-16L1 concentrations from 4 µg/µl titrated down to 0.0 µg/µl in 1:2 
steps and tested for their reactivity to (A) HPV 16L1 and (B) to HPV 18L1. In a second experiment, 
the same mAb were preincubated with MBP-16L1 concentrations from 3 µg/µl titrated down to 0.0 
µg/µl in 1:3 steps and again tested for their reactivity to (C) HPV 16L1 and (D) HPV 18L1. Data 
showed that at least 1µg/µl MBP-16L1 is sufficient to block both HPV-16 type-specific and cross-
reactive epitopes.   
 
 
Specificity of MBP16L1 blocking activity  
Using the mAb, we were able to investigate whether the blocking activity of MBP-16L1 was 
specific or not; whether only HPV 16 specific and cross-reactive epitopes are blocked and not 
other epitopes specific for other HPV types. To this end, the following mAb were 
preincubated with different concentrations of MBP-16L1 as described in the later section: 
 
H16.5A strongly reactive only with HPV16 
H16.8B strongly reactive with both HPV16 and HPV18 
H16.D9 strongly reactive with both HPV16 and HPV6 
H18.K2 strongly reactive only with HPV18 
H6.N8  strongly reactive only with HPV6 
 
After preabsorption, the different mAb were examined with GST-L1 fusion proteins of HPV 
16, 18 and 6. As expected neither H18.K2 nor H6.N8 reacted with HPV16 (Figure 4A) but 
only with HPV18 (Figure 4B) and 6 respectively (Figure 4C). Furthermore, these two mAb 
had not been affected with the preabsorption process with MBP-16L1 and their reactivity to 
the specific HPV type remain more or less stable up to an MBP-16L1 concentration of 
1µg/µl; however, preincubation with higher concentrations may also decrease the binding 
activity even to the specific HPV type. As earlier concluded from the previous blocking 
experiments, the data confirms again that HPV16 cross-reactive antibodies lose their 
reactivity faster than the type-specific ones and at 1 µg/µl, they all lost ≥80% of their binding 
activity (Figure 4).   
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Figure 4. Determination of specificity of MBP-16L1 blocking activity. Three HPV 16, one HPV18 
and one HPV 6  specific mAb were preincubated with different MBP-16L1 concentrations from 3 
µg/µl titrated down to 0.0 µg/µl in 1:3 steps and tested for their specific reactivity to (A) HPV 16L1 
(B) HPV 18L1 and (C) HPV 6L1. None of HPV 18 or 6 type-specific mAb was blocked. 
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Appendix 4 
 
Titration of MBP-16L1tag blocking activity using human sera  
Since the main objective of this project is to differentiate the specific from cross-raective 
signals in serological studies, it was important to check if similar results concerning the 
blocking activity of MBP-16L1 could be obtained when use selected human sera instead of 
the experimentally produced mAb. We wanted by using human sera to titrate the blocking 
activity of MBP-16L1 and determine the appropriate concentration that could achieve almost 
complete inhibition of HPV 16 specific and cross-reactive epitopes recognized by a serum. 
Three sera from Madras-Algiers study and one from Rom case-control study were chosen for 
these experiments and they were tested in duplicates: 
 
 
    Madras-Algiers           Serum 1 (326)      strongly reactive with only HPV16 
         Serum 2 (603)      strongly reactive with only HPV 18 
         Serum 3 (523)      strongly reactive with both HPV 16  
                                                                             and 18 
    Rom (case-control)     Serum 4 (20210)     strongly reactive with only HPV 5 
 
 
The sera were preincubated as previously described with different concentrations of MBP-
16L1 and then their reactivity to GST-L1 of HPV 16, 18 and 5 was tested in ELISA. 
The HPV16 assay showed that both S3 and S4, as expected, did not react and the recorded 
activity was almost less than 20%. More than 80% of S1 reactivity was blocked by 
preapsorption with 0,1µg/µl MBP-16L1, in contrast, S2 which in previous investigations 
done by other colleagues was strongly reactive with both HPV16 and 18 lost 80% of its 
reactivity  
Therefore, and to ensure complete blocking, 2 µg/µl MBP-16L1 will be applied in the 
following experiments.    
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Figure 5. Titration of MBP-16L1 blocking activity using human sera. Four human sera with 
different reactivity patterns were preincubated with different MBP-16L1 concentrations from 3 µg/µl 
titrated down to 0.0 µg/µl in 1:3 steps and tested for their reactivity to (A) HPV16L1 (B) HPV18L1 
and HPV 5L1. None of HPV 18 or HPV 5 type-specific sera was blocked.  
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